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VEGFC but not VEGFD to an active ligand. Consistent with these ex vivo findings, mouse genetic studies
demonstrate that ADAMTS3 is required for lymphatic development in a manner identical to VEGFC and
CCBE1, and that CCBE1 is required for lymphangiogenesis stimulated by VEGFC but not VEGFD in vivo.
These studies reveal that lymphangiogenesis is regulated by two distinct proteolytic mechanisms of ligand
activation: one in which VEGFC activation by ADAMTS3 and CCBE1 spatially and temporally patterns
developing lymphatics, and one in which VEGFD activation by a distinct proteolytic
mechanism may stimulate lymphatic growth during inflammation or wound healing.
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ABSTRACT 
PROTEOLYTIC ACTIVATION BY ADAMTS3 DEFINES DISTINCT MECHANISMS 
OF LYMPHANGIOGENESIS MEDIATED BY VEGFC AND VEGFD 
Hung M. Bui 
Mark L. Kahn 
Lymphangiogenesis is supported by two homologous VEGFR3 ligands, VEGFC and 
VEGFD. VEGFC is required for lymphatic development, while VEGFD is not. VEGFC 
and VEGFD are proteolytically cleaved after cell secretion in vitro, and recent studies 
have implicated the protease ADAMTS3 and the secreted factor CCBE1 in this process. 
How ligand proteolysis is controlled at the molecular level and how it regulates 
lymphangiogenesis remain poorly understood because these complex molecular 
interactions have been difficult to follow ex vivo and test in vivo. In the present study, we 
use new biochemical and cellular tools to demonstrate that an ADAMTS3-CCBE1 
complex can form independently of VEGFR3 is required to convert VEGFC but not 
VEGFD to an active ligand. Consistent with these ex vivo findings, mouse genetic studies 
demonstrate that ADAMTS3 is required for lymphatic development in a manner identical 
to VEGFC and CCBE1, and that CCBE1 is required for lymphangiogenesis stimulated by 
VEGFC but not VEGFD in vivo. These studies reveal that lymphangiogenesis is 
regulated by two distinct proteolytic mechanisms of ligand activation: one in which 
VEGFC activation by ADAMTS3 and CCBE1 spatially and temporally patterns 
developing lymphatics, and one in which VEGFD activation by a distinct proteolytic 
mechanism may stimulate lymphatic growth during inflammation or wound healing. 
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1 
CHAPTER ONE 
Introduction 
1.1 Lymphatic system 
In vertebrates, lymphatics are a part of the circulatory system that develops from pre-
existing blood vessels. The lymphatic system plays important roles, not only by 
transporting interstitial fluid and absorbing lipids, but also by providing a conduit for 
immune cells. The discovery of lymphatic vasculature dates back to the ancient time in 
the record of Hippocrates (5th century BCE) and Herophilos (3rd century BCE). The idea 
of lymphatic vasculature was further developed in 17th century by the works of William 
Harvey, who discovered a separate system from the blood circulation; that was followed 
by Thomas Bartholin's description on lymphatic vessels. However, it was not until the 
20th century that the anatomic features of the lymphatic vasculature were extensively 
characterized. Florence Sabin was the first who suggested cardinal veins are the initial 
site of lymphatic development (Sabin, 1902), which has recently been demonstrated by 
modern technologies of lineage tracing and live imaging (Yaniv et al., 2006; Srinivasan 
et al., 2007). Discoveries on lymphatic system have bloomed in recent years that provide 
better understanding of the system, as well as facilitate new approaches to address 
unanswered questions.         
The lymphatic system is a network of lymphatic vessels, lymph nodes, the spleen, and the 
thymus (Fig. 1). First, lymph vessels, aka lymphatics, carry lymph (or interstitial fluid) in 
one direction from blood vessels back to the heart. Lymphatics consist of a hierarchy of 
transporting vessels that are separated by lymphatic valves (mentioned later). Secondly, 
2 
lymph nodes (LN) are secondary lymphoid organs, in which lymphocytes come into 
contact with antigen to trigger an immune response. Primary lymphoid organs (like bone 
marrow), on the other hand, are the sites of lymphocyte generation. LNs share mutual 
development with lymphatic vasculature during early stages of lymphatic development, 
which allows LNs to act as junctions between lymphatic vasculature and lymphoid 
tissues. This connection enables antigens to enter mature LNs via afferent lymphatic 
vessels and to present to lymphocytes in the LN. Thirdly, the spleen is a bean-shaped 
organ located in the upper left side of the abdomen, which functions as blood filter. The 
macrophage lining in the spleen engulfs and eliminates pathogens and dead cells. 
Another important function of the spleen is to generate and release lymphocytes into 
blood stream. Lastly, the thymus is a lymphoid tissue located in the upper chest under the 
breastbone. The thymus only develops until the time of puberty when it shrinks and 
gradually blends in with surrounding tissues. In the thymus, immature lymphocytes 
develop into T lymphocytes (T cells) by the thymic environment.  While maturing and 
multiplying in the thymus, each T cell is programmed to respond to a specific chemical 
identification marker, i.e. an antigen. 
 
 
 
 
 
Figure 1. The human lymphatic system. 
3 
1.2 Lymphangiogenesis 
Lymphangiogenesis is defined as a process of lymphatic vessel formation from pre-
existing blood vessels.  
1.2.1 Early development stage 
In mice, lymphatic endothelial cells (LECs) arise from pre-existing blood endothelial 
cells via a process of stepwise specification (Fig. 2).  
 
 
 
 
 
 
 
Lymphangiogenesis begins at embryonic day (E) 9.5, when a subpopulation of cardinal 
vein (CV) blood endothelial cells (BECs) enters the “lymphatic bias” stage. These cells 
orient to one side of the CV as they develop into LEC progenitors. The first molecular 
marker of this process is the transcription factor Lyve1, which is specifically expressed by 
venous BECs, which later form LEC progenitors (Oliver, 2004). The first marker of true 
LEC progenitors is the transcription factor Prox1 (Wigle and Oliver, 1999). The 
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Sabin’s concept. They showed that endothelial cells
(ECs) from the anterior cardinal vein start to express
LYVE1 around embryonic day (E) 9.0–9.5 in the mouse
(Oliver, 2004). It still remains unclear which gene or the
molecule produced is responsible for this expression 
 
in
vivo
 
 and whether LYVE1 expression is essential for the
metamorphosis from venous endothelial cell (VEC)
to LEC. Studies investigating LYVE1 expression in ECs
derived from mouse embryonic stem (ES) cells suggest
that this expression is induced via VEGFR-3 signalling
(Suzuki et al. 2005). The assumed function of LYVE1
is the hyaluronan transport across the wall of the
lymphatic vessel (Jackson et al. 2001). No published
data are available that show the necessity of LYVE1
gene activity for ECs to gain lymphatic competence. In
his review, Oliver (2004) reported data from a personal
communication with N. W. Gale, G. Thurston and G. D.
Yancopolous, who found no alteration in the lymphatics
in mice with targeted deletion of the 
 
LYVE1
 
 gene. To the
best of our knowledge, these data remain unpublished.
Further studies on 
 
LYVE1
 
 knock-out mice might illumin-
ate that question. Oliver called this stage of the cells,
as previously argued by Wigle et al. (2002), ‘lymphatic
endothelial cell competence’ (Fig. 1). At this critical
stage the VECs start to express LYVE1 and gain the abil-
ity to react to a specific unknown lymphatic inducing
signal (Oliver, 2004). This signal triggers the expression
of Prox1 by the cells of one side of the anterior cardinal
vein (Fig. 1). This expression occurs around E9.0–10.5, a
few hours after LYVE1 expression, and is restricted to a
group of cells on one side of the anterior cardinal vein.
This cell group later starts to sprout and bud from the
vein, attracted by a guidance signal (Wigle & Oliver,
1999) (Fig. 1). It has been documented that VECs of
Prox1-deficient mouse embryos stop sprouting and
budding from the VECs at E11.5–12.0, they do not
attain the phenotype of LECs and as a consequence
those mice fail to develop lymph sacs (Wigle et al. 2002).
Investigating the expression of specific lymphatic markers
VEGFR-3, LYVE1 and CCL21 in LECs of Prox1-deficient
embryos showed that Prox1 activity is not only essential
for the maintenance of sprouting and budding of the
ECs, but that it has an additional function in determining
the ‘lymphatic bias’ of the Prox1-positive LECs (Wigle et al.
Fig. 1 Development of the lymph sacs 
in the mouse, through budding and 
sprouting of endothelial cells. The 
autonomous endothelial cells of the 
anterior cardinal vein start to express 
LYVE1 around E9.0–9.5. The cells on one 
side of the vein follow the lymphatic 
bias and start to express Prox1. For 
the budding and sprouting of 
lymphendothelial cells at E10.5–11.5, 
the Prox1 expression of the 
lymphendothelial cell precursors cells 
is a prerequisite to react to a guiding 
signal. VEGF-C seems to be involved in 
this guidance and signalling process. 
When the lymphendothelial cells start 
to migrate, they already express most 
molecules specific for the 
lymphendothelium such as LYVE1, 
Prox1, CCL21 and VEGFR-3. Around 
E11.5–12.5 the lymphatic and the blood 
vascular system are separated and the 
lymphatic vessel development and the 
lymph node development follow 
different pathways emerging from 
the lymph sacs. (Modified after Oliver 
& Alitalo, 2005.)
Figure 2. Early development of mouse lymphatic system (E9.0 – E11.5) (adapted 
from Blum and Pabst, 2006).  
4 
transcription factors Sox18 and Coup-TFII are required for Prox1 expression and 
maintenance. Whereas loss of Sox18 results in the absence of LEC progenitors (François 
et al., 2008), COUP-TFII is essential for the specification of lymphatic endothelial cells 
(LECs). COUP-TFII down regulates Notch activity, resulting in Prox1 expression 
(Srinivasan et al., 2010). By the end of the “lymphatic bias” stage, PROX1+ cells, now 
called LEC progenitors, show increased expression of lymphatic genes and decreased 
expression of blood endothelial genes.  
The “lymphatic specification” stage begins by E10.5, when LECs start to sprout from the 
cardinal vein. A subset of LEC progenitors expresses PODOPLANIN (PLDN), a specific 
marker of true LECs, and bud from the CV (Yang et al., 2012). After departing from the 
vein, LECs connect with each other through VE-Cadherin adhesion junctions.  Finally, 
LECs migrate along the embryo’s anterior-posterior axis to form intermediate structures 
called ‘lymph sacs’ by E11.5. This process requires signaling from vascular endothelial 
growth factor-C (VEGFC) via its receptor, vascular endothelial growth factor receptor 3 
(VEGFR3), and co-factor, Neuropilin 2 (Nrp2) (Jeltsch et al., 1997; Yuan et al., 2002). 
PROX1+ LEC progenitors fail to exit from the CV in Vegfc-deficient mice (Karkkainen et 
al., 2004). VEGFC/VEGFR3 in vivo activity is specific for lymphatic growth, since only 
LECs are responsive to VEGFC growth signaling (Jeltsch et al., 1997). Several 
regulatory proteins also influence the process of LEC migration. Ephrin B2 facilitates 
VEGFR3 internalization, which is required for VEGFR3 activation (Wang et al., 2010). 
At this point, the mutual development of the lymphatic vasculature and the lymphoid 
organs, such as LNs, halts and the two systems develop independently of each other 
(Yokota et al., 1999; Muller et al., 2003; Cupedo et al., 2004). 
5 
1.2.2 Lymphatic vasculature 
The lymphatic vasculature continues to develop through sprouting of lymph sac LECs to 
form a primitive lymphatic plexus at E14.5. This structure remodels further after E15.5 to 
establish the mature lymphatic system, in which the interstitial fluid (lymph) enters the 
lymphatic system through initial lymphatic capillaries (Fig. 3).  
 
 
 
 
 
 
 
 
Figure 3. The organization of the lymphatic vascular system (Hajjami and Petrova, 2008). 
 
Initial lymphatic capillaries are comprised of a monolayer of LECs, and are blind-ended 
(Swartz and Skobe, 2001). The capillaries lack basal lamina, but are supported by 
anchoring filaments that connect to nearby vessels (Leak and Burke, 1968). The unique 
structure of lymphatic capillaries allows them to function as one-way valves, which 
prevents back-flow of interstitial fluid. The lymph is then drained into pre-collecting 
1064 Histochem Cell Biol (2008) 130:1063–1078
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(A, D, E, and K) and dietary fat, released by enterocytes in
the form of lipid particles called chylomicrons. Further-
more, the lymphatic system is an important part of immune
surveillance by carrying antigens and antigen presenting
cells from the interstitium to be displayed for B and T cells
in the lymph nodes. In addition to these physiological tasks
the lymphatic system plays a major role in a number of
pathologic conditions, including lymphedema, inXamma-
tory diseases, and tumor metastasis.
Present in the skin and in most internal organs, with the
exception of avascular structures such as epidermis, hair,
nails, cartilage, and cornea, and some vascularised organs
such as the brain, bone marrow, and retina, the lymphatic
vasculature is composed of vessels with distinct morpho-
logical features (Fig. 1). Similar to blood capillaries, lym-
phatic capillaries consist of a single layer of thin-walled,
non-fenestrated lymphatic endothelial cells (LECs), but
they diVer in that they are not ensheathed by pericytes or
smooth muscle cells (SMCs), and have an absent or poorly
developed basement membrane. In addition, they lack tight
junctions and adherens junctions, which allow easy access
for Xuid, macromolecules, and cells into the vessel lumen
(Leak 1976). Endothelial cells of lymphatic capillaries are
oak leaf shaped and are interconnected by specialized
discontinuous button-like junctions, whereas collecting
lymphatic vessels downstream have continuous zipper-like
junctions found also in blood vessels (Baluk et al. 2007).
Overlapping endothelial cell–cell contacts (also called pri-
mary valves) in initial lymphatic vessels prevent Xuid
escaping back into the interstitial space (Schmid-Schönbein
2003; Trzewik et al. 2001). Lymphatic capillary endothelial
cells are closely linked to the surrounding extracellular
matrix by elastic Wbers known as anchoring Wlaments (Gerli
et al. 1991; Leak and Burke 1968), which prevent vessel
collapse in conditions of high interstitial pressure, indeed in
this condition the junctions of the initial lymphatics open
and the anchoring Wlaments stretch, allowing Xuid to move
into the vessel. Anchoring Wlaments are made of Wbrillin
(Gerli et al. 2000; Solito et al. 1997), a large glycoprotein
that contains an Arg–Gly–Asp (RGD) motif capable of
binding !v"3 integrins, which are transmembrane glyco-
proteins that cluster at focal adhesion plaques. Pre-collector
lymphatic vessels are characterized by the alternation of
areas with the same structural simplicity as initial lym-
phatic capillaries and areas with a well-developed muscular
coat, but the ultrastructural features of these diVerent por-
tions do not diVer, and anchoring Wlaments are present in
both (Scavelli et al. 2004). The pre-collecting lymphatic
vessels merge into collecting lymphatic vessels, and the two
types of vessels have a basement membrane, and are sur-
rounded by SMCs with intrinsic contractile activity to pro-
mote lymph Xow. The latter is also due to the contraction of
surrounding skeletal muscles, as well as arterial pulsations.
Like veins, the larger lymphatic vessels contain one-way
intraluminal valves that aid in lymph propulsion by prevent-
ing backXow (Leak and Burke 1966; von der Weid and
Zawieja 2004). Compared to blood vessels, the lymphatic
vasculature is a low Xow and low pressure system.
Development of lymphatic vasculature
Embryonic development concepts
The Wrst description of the lymphatic system dates back to
the seventeenth century, when Gasparo Aselli identiWed
lymphatic vessels as ‘‘milky veins’’ in the mesentery of a
‘‘well-fed’’ dog (Asellius 1627). However, the embryonic
origin of lymphatic vessels remained unclear for a long
time until F. Sabin (1902, 1909) and F. Lewis (1905) postu-
lated, at the beginning of the twentieth century, that LECs
are derived from the venous endothelium. This “centrifu-
gal” theory proposes that endothelial cells bud oV from the
veins during early embryonic development and form primi-
tive lymph sacs in the jugular region (reviewed by Oliver
Fig. 1 Organization of lymphatic vascular system. The lymph is col-
lected by a network of blind-ended lymphatic capillaries and is trans-
ported by pre-collector lymphatic vessels and collecting lymphatic
vessels, which are emptied into veins in the jugular region. Lymphatic
capillaries consist of thin-walled lymphatic endothelial cells with over-
lapping junctions which look like valves. Anchoring Wlaments, co -
taining Wbrillin, connect lymphatic capillaries to the extracellular
matrix and prevent vessel collapse during increased interstitial pres-
sure. The pre-collector and collecting lymphatic vessels have a base-
ment membrane, are surrounded by smooth muscle cells (red) and
co tain intralumi al valves th t prevent lymph blac Xow
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vessels, which contain bicuspid one-way valves located at irregular intervals, and 
incomplete coverage by smooth muscle cells (Sacchi et al., 1997). They have a dual role 
— first, as lymph transporters, pumping at regions containing smooth muscle cells, and 
second, as fluid absorbers, where the smooth muscle cell layer is absent. Pre-collecting 
vessels drain into the larger collecting vessels. Collecting lymphatic vessels have 
complete smooth muscle cell coverage of their walls to facilitate lymph transport and 
intraluminal valves form to prevent retrograde flow. The collecting lymphatics bring fluid 
into and out of the LN via afferent and efferent vessels, respectively. They connect to the 
blood circulation at the site of lymphovenous valves, located at the junctions of the left 
and right subclavian veins and the lymphatic duct. These valves prevent blood from 
filling the lymphatic system through a mechanism involving CLEC2, the platelet receptor 
activated in response to LECs (Hess et al., 2014). By contracting, collecting vessels force 
lymph back to the blood circulation via the lymphovenous valves, completing the one-
way flow of lymph facilitated by the lymphatic system (Fig. 4).  
 
 
 
 
 
 
Figure 4. The lymphatic vasculature and direction of lymph flow (adapted from Margeris and Black, 
2012).  
2. ANATOMY OF THE LYMPHATIC
SYSTEM
The lymphatic system is composed of a network of
vessels, termed lymphatics, lymph nodes and lymphoid
organs. The interstitial fluid enters through the small
lymphatic capillaries (also called initial or terminal
lymphatics) that gradually combine to form larger
diameter vessels, namely the pre-collectors, collectors,
trunks and ducts. The interstitial fluid, which is
termed lymph when inside the lymphatics, is pumped
slowly by the contraction of the lymphatic vessels,
which contain smooth muscle in their walls. Retro-
grade flow is prevented by a series of one-way valves.
Figure 1 shows a simplified schematic diagram of the
lymphatic system.
The lymphatic network is asymmetrical: the right-
hand side of the head and thorax and the right arm
drain into the right subclavian vein, whereas the lym-
phatic vessels of the rest of the body converge at the
thoracic duct, which empties at the junction of the
jugular and left subclavian veins.
2.1. Initial lymphatics
Initial lymphatic capillaries have a diameter of approxi-
mately 10–60 mm with a wall thickness ranging from 50
to 100 nm and are blind-ended. Electron microscopy
revealed that lymphatic capillaries are usually collap-
sed with irregular walls and do not have a continuous
basal lamina. They comprise a monolayer of non-
fenestrated endothelial cells [4]. They are supported
by anchoring filaments (6–10 nm in diameter) that
keep them from completely collapsing when inter-
stitial fluid pressure increases [10]. Their unique
structure allows them to function as a one-way valve
system that allows fluid to flow into them and then to
close in order to stop back-flow as the internal pressure
rises. Trzewik et al. [11] demonstrated this function exper-
imentally, although they were not the first to postulate
the existence of primary lymphatic valves. Leak &
Burke [10] investigated the structure of the lymphatic
capillaries, and speculated that they could function as
valves, although at that time no proof was provided.
2.2. Pre-collecting lymphatics
The pre-collecting lymphatics connect the capillaries to
the collecting vessels. They contain bicuspid one-way
valves, but unlike the collecting vessels, where they
are located at regular intervals, their distribution
becomes more irregular towards the capillary vessels,
and may comprise a single leaflet [6,12]. The pre-collec-
tors contain one or more layers of smooth muscle cells
within their walls, and are capable of performing spon-
taneous contractions. However, portions without
muscle exist; in these parts, the endothelial layer in
the pre-collectors is similar to that of initial lympha-
tics with a discontinuous basal lamina. Thus, these
structures absorb fluid instead and therefore the pre-
collectors have a dual role: absorption and propulsion
of lymph [12].
2.3. Collecting lymphatics
The larger collecting lymphatics differ from the capil-
laries and pre-collectors, as they have a complete
basal lamina and therefore the primary lymphatic
valves are absent. They contain another type of valve
that prevents retrograde flow: the secondary valve.
The wall structure is similar to that of blood vessels.
Three layers can be identified—the intima, media and
adventitia [13].1 They are composed of endothelial
cells, smooth muscle and collagen fibres, respectively.
It has been observed that the muscle bundles are
arranged in a hellicoidal manner in both collecting
and pre-collecting vessels [12]. The part of the vessel
between two valves is known as a lymphangion
(figure 2).
pulmonary
lymphatic
capillaries
pulmonary circulation
1. lymphatic venous anastomosis
2. node blood supply
4. efferent lymphatic vessels
5. lymphangion
6. lymph node
3. afferent lymphatic vessels
systemic circulation
interstitium
lymphatic capillaries
node
1
2
3
4
5
6
afferent
lymphatic
vessels
Figure 1. The lymphatic system. Adapted with permission from Quere [9].
1An oblique layer has been reported by Telinius et al. [14] in the
human thoracic duct.
602 Review. Modelling the lymphatic system K. N. Margaris and R. A. Black
J. R. Soc. Interface (2012)
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1.2.3 Lymphatic defects 
Defects in lymphatic vasculature formation can lead to disruption of the drainage of 
interstitial fluids back into the cardiovascular system, resulting in lymphedema, 
chylothorax, and other consequences. One of the consequences of lymphatic defects is 
primary lymphedema, caused by hereditary genetic disorders. Primary lymphedema is 
associated with disordered lymph drainage, results in lymph dysplasia or lethality (in case 
of some homozygous mutants). For example, in Hennekam’s syndrome, mutations in 
CCBE1  (CCBE1 collagen and calcium binding EGF domain -1) lead to lymphedema and 
mental retardation in human patients (Alders et al., 2009). CCBE1-null mice die due to 
lack of lymphatic vasculature, which results in respiratory failure at birth (Jakus et al., 
2014). In Milroy’s syndrome, a missense mutation in the VEGFR3 kinase domain leads 
to congenital lymphedema in humans, and limb swelling in Chy mice (a mouse model of 
Milroy’s disease) (Butler et al., 2007; Karkkainen et al., 2001). Another consequence of 
lymphatic defects is obesity due to the fact that intestinal lymphatic vessels are 
responsible for lipid absorption in the form of chylomicrons and fat transportation in the 
bloodstream. The link between lymphatic vasculature defects and obesity were 
demonstrated in a mouse model heterozygous for a PROX1 mutation, which developed 
obesity (Harvey et al., 2005). Moreover, Chy mice have abnormal fat accumulation, 
along with the reported lymphedema (Rutkowski et al., 2010). Just as lymphatic defects 
have been shown to cause excess fat deposition, it appears that lymphatic defects can 
result in obesity-associated metabolic diseases such as diabetes and cardiovascular 
diseases (e.g. atherosclerosis). In addition, lymphatic vasculature has also been reported 
to be a route for tumor cells to metastasize in cancer (reviewed in Alitalo, 2011). The 
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high interstitial pressure in malignant tumors enables cells to enter lymphatic vessels and 
to travel to different sites in the body through lymph flow, resulting in metastasis. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Examples of Milroy’s patients (adapted from Gordon et al., 2013). 
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1.3 Vascular endothelial growth factor (VEGF-) C 
1.3.1 Vascular endothelial growth factor family 
VEGF/ PDGF (platelet-derived growth factor) family is a group of the cysteine-knot 
superfamily of signaling molecules, which are characterized by the presence of eight 
conserved cysteine residue forming the cysteine-knot structure in the VEGF-homology-
domain (VHD) (Vitt et al., 2001). In mammals, the VEGF family includes five well-
known ligands, VEGFA, VEGFB, VEGFC, VEGFD and PIGF (placental-induced growth 
factor), plus two less studied ligands, VEGFE and VEGFF. These molecules display 
various essential roles during embryonic development (including angiogenesis – 
sprouting process of new blood capillaries from pre-existing vessels; and 
lymphangiogenesis) and in adulthood.  
 
 
 
 
 
 
 
 
 
Figure 6. Sequence alignment of VEGF family members and their isoforms (Takahashi et al., 2005). 
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A. VEGFA 
VEGFA (aka VEGF) was first characterized as a vascular permeability factor in tumor 
cells (Senger et al., 1983), thus its function was identified as tumor-secreted cytokine 
stimulating angiogenesis (Rini and Small, 2005). Biochemical studies further revealed 
that VEGFA exists in four mature isoforms (by alternative splicing) including VEGF121, 
VEGF165, VEGF189 and VEGF206  (Tischer et al., 1991); among which, VEGF165 is the 
dominant isoform. In vitro, VEGFA has been shown as a pro-angiogenic protein by 
inducing proliferation and tube formation of endothelial cells (Leung et al., 1989); as 
well as a potent survival factor for these cells (Gerber et al., 1998). Furthermore, in vivo 
study of VEGFA demonstrated the protein to be indispensable during embryogenesis as 
deletion of Vegfa gene leads to cardiovascular abnormalities, thus resulting in embryonic 
lethality (Carmeliet et al., 1996). VEGFA also regulates a number of angiogenic 
processes such as wound healing and tumor growth in adult animals (Brown et al., 1992; 
Larcher et al., 1998; Rossiter et al., 2004). 
 
B. VEGFB 
Although VEGFB was demonstrated to promote angiogenesis through activation of AKT 
and eNOS pathways (Silvestre et al., 2003), the precise role of VEGFB in vivo remains 
unknown. This is illustrated by the fact that Vegfb-deficient mice are viable and fertile, 
with a mild phenotype consisting of smaller hearts and impaired recovery from cardiac 
ischemia (Bellomo et al., 2003). Expression of VEGFB in vitro yields two different 
isoforms (by alternative splicing), VEGF-B167 and VEGF-B186; the former associates with 
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membrane glycosaminoglycans for extracellular matrix (ECM) anchoring, while the latter 
is likely to diffuse freely throughout the body (Olofsson et al., 1996).  
 
C. VEGFC 
VEGFC is the only VEGF family member that induces selective lymphangiogenesis 
without promoting angiogenesis during embryonic development in vivo (Jeltsch et al., 
1997).  Mice with complete loss of Vegfc lacked lymphatic vasculature and died of 
edema, whereas heterozygous Vegfc-deficient mice showed cutaneous lymphedema and 
hypoplasia lymphatic vessels (Karkkainen et al., 2004). In addition, overexpression of 
VEGFC in adult tumor transgenic mice showed higher lymphatic invasion and metastatic 
potential in various types of cancers (Mandriota et al., 2001; Wang et al., 2013; Fujimoto 
et al., 2004; He et al., 2004). These data demonstrate an indispensable role of VEGFC 
during early lymphangiogenesis, as well as maintaining a role in lymphangiogenesis in 
adult mice. More insights on VEGFC properties have been revealed from in vitro studies. 
Unlike VEGFA or VEGFB, VEGFC protein structure contains two peptide extensions (at 
both N- and C- termini) flanking the central VHD. This illustrates why VEGFC is 
generated as a precursor protein, which requires to be proteolytically processed to gain 
full activation as an active ligand (mentioned later). Interestingly, among the members of 
the VEGF family, VEGFC is highly homologous to VEGFD despite the fact that their 
biological functions are very different. How the two homologous proteins plays different 
roles in lymphangiogenesis remains unanswered yet.     
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D. VEGFD 
VEGFD is highly homologous to VEGFC, in term of protein structure (Orlandini et al., 
1996; Achen et al., 1998) and also acts as a lymphatic factor by driving lymphatic 
endothelial and vessel growth in adult animals (Rissanen et al., 2003; Saaristo et al., 
2002). Nevertheless, loss of VEGFD does not alter lymphatic development in the mouse 
or fish (Koch et al., 2009; Astin et al., 2014). It is not yet clear how VEGFD works in 
vivo as a dispensable factor during early lymphangiogenesis but becomes active in adult 
animals. On the other hand, in vitro studies showed that VEGFD also undergoes 
proteolytic processing (McColl et al., 2007), like VEGFC, to gain its active state. 
Although it is not yet known exactly how VEGFC and VEGFD ligands are 
proteolytically regulated, it is interesting to understand the relationship of these two 
lymphatic factors and what makes them distinctively different towards regulating 
lymphangiogenesis.   
E. The other VEGF family members 
PIGF, originally discovered in the placenta, is a dispensable angiogenic factor as Pigf – 
deficient mice showed impairs in angiogenesis and collateral growth (Carmeliet et al., 
2001). Overexpression of PIGF in transgenic mice enhanced vascular permeability and 
led to an increase in number of skin blood vessels (Odorisio et al., 2002; Oura et al., 
2003). VEGFE and VEGFF are the least studied of the factors. While VEGFE, especially 
its VEGF-ENZ-2 isoform (Lyttle et al., 1994) is regarded as a potent angiogenic factor 
(Meyer et al., 1999); the functional activity of VEGFF (identified from viper venom) is 
not yet known.  
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1.3.2 VEGF receptors and VEGFR3 (FLT4) 
The VEGF-member ligands induce signaling cascades via three receptor tyrosine kinases 
(RTKs): VEGFR1, expressed in monocytes and macrophages, VEGFR2, expressed in 
vascular endothelial cells, and VEGFR3, expressed in lymphatic endothelial cells. These 
receptors share certain common aspects with other RTK families like the platelet-derived 
growth factor receptors (PDGFRs) and the epidermal growth factor receptors (EGFRs). 
Like these receptors, the VEGF- receptors dimerize in order to be activated and to 
transduce intracellular signals. The VEGF- receptors are composed of seven extracellular 
immunoglobin (Ig)-like loops, a transmembrane domain, an autoinhibitory 
juxtamembrane domain, a split tyrosine kinase domain and intracellular C-terminal tail 
(Zachary and Gliki, 2001).  
VEGFR signaling is initiated by binding of dimeric VEGF ligands to an IgG-like domain 
of the receptors, either in a cis (from the same cell) or trans (from adjacent cells) manner. 
VEGFR dimerization is “ligand-mediated”, meaning that receptor dimerization is solely 
dependent on ligand-receptor interactions (review in Lemmon and Schlessinger, 2010), 
which are further stabilized by contact points between the two extracellular domains 
(Yang et al., 2010). When the receptor is inactive, the catalytic kinase domain is auto-
inhibited by the juxtamembrane domain. Juxtamembrane autoinhibition acts in cis to 
make stable contacts with the kinase domain of the same receptor, thus preventing 
phosphorylation of the catalytic tyrosine residues (Nolen et al., 2004). In accordance with 
the general model of tyrosine kinase receptor activation, VEGFRs dimerize upon ligand 
binding, leading to trans-phosphorylation of the receptor tyrosines, which in turn 
weakens the cis- autoinhibitory juxtamembrane domain interaction (Hubbard, 2004). The 
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autophosphorylation of RTKs occurs in a precise order. “First-phase” 
autophosphorylation refers to phosphorylation of specific tyrosine residues that enhances 
the kinase catalytic activity (Favelyukis et al., 2001). Subsequent autophosphorylation 
events generate docking phosphotyrosine sites, which recruit cytoplasmic signaling 
molecules containing Src homology-2 (SH2) and/or Phosphotyrosine-binding (PTB) 
domains (Pawson, 2004; Schlessinger and Lemmon, 2003). These molecules are 
recruited to RTKs either through direct binding to the receptor phosphotyrosines or 
indirectly via docking proteins such as Gab1 (the Grb-associated binder) (Gu and Neel, 
2003). These docking proteins then recruit and phosphorylate downstream effector 
kinases.  With multiple phosphotyrosine residues in the catalytic kinase domain, activated 
receptors could trigger multiple signaling cascades, thus acting as a node in a complex 
signaling network. 
VEGFR3 (or FLT4) regulates early angiogenesis but becomes a lymphatic-specific RTK 
around mid-gestation onwards (reviewed in Olsson et al., 2006). This receptor is 
synthesized as a 195kDa protein precursor, which is proteolytically cleaved in the fifth 
Ig-like loop resulting in a N-terminal peptide disulfide-bonded to the rest of the protein 
(Pajusola et al., 1994). Human VEGFR3, by alternative splicing, exists as two protein 
isoforms: predominant VEGFR3-long and VEGFR3-short, which has a shorter 
cytoplasmic tail (Pajusola et al., 1993). VEGF-C/-D binding, via co-receptor NRP2 
(Yuan et al., 2002), activates VEGFR3 to promote lymphatic vasculature development. It 
has previously been shown that VEGFC/VEGFR3 signaling is essential for proliferation 
and migration of lymphatic endothelial cells (LECs) in vitro (Jeltsch et al., 1997). It is 
also true in vivo, as Chy mice (heterozygous for VEGFR3 kinase domain mutation) 
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display lymphedema, swelling caused by lymphatic vasculature defects (Karkkainen et 
al., 2001).  
Upon VEGF-C/-D binding, VEGFR3 undergoes homo-dimerization with an adjacent 
receptor that triggers trans-phosphorylation at Tyr1068 residue located in the kinase 
domain (Fig. 7). Mutagenesis analysis confirmed that this tyrosine residue is important 
for regulating kinase activity (Salameh et al., 2005), thus making it the site of “first-
phase” autophosphorylation. The following phosphorylation can take place at six other 
tyrosine residues (Tyr1063, Tyr1230, Tyr1231, Tyr1265, Tyr1337 and Tyr1363) on the receptor. 
Besides, integrins can induce VEGFR3 phosphorylation at other different tyrosine 
residues, which is independent of VEGF-C/-D binding and receptor kinase activity 
(Galvagni et al., 2010).  
S-S 
Plasma membrane 
S-S 
Tyr1068 
CRKI/II 
SHC – GRB2 complex 
PLCγ 
PI3K 
VEGFC 
VEGFC 
 
Figure 7. VEGFC-induced VEGFR3 signaling cascades. The disulfide (S-S) bond represents the fifth 
immunoglobulin-like (Ig-like) domain of VEGFR3, which is proteolytically processed.  
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Most of those VEGFR3 phosphorylation sites have been studied in vitro (Mäkinen et al., 
2001; Wang et al., 2004). In summary, phosphorylated Tyr1063 interacts with the adaptor 
protein, CRKI/II. This in turn activates MKK4, which acts via the c-Jun N-terminal 
kinase (JNK) pathway to promote cell survival. Other phosphotyrosines are responsible 
for generating docking sites for recruitment of SH2/ PTB containing proteins such as 
SHC-GRB2 complex, PLC-gamma and PI3K kinase that lead to signaling of ERK1/2 
(cell proliferation) or AKT (cell survival) pathways.  The first pathway, via SHC-GRB2 
complex, activates c-Raf-1, which facilitates subsequent phosphorylation/ activation of 
downstream kinases MEK and ERK1/2, a cell proliferation regulator. In the second 
pathway, activated VEGFR3 recruits and phosphorylates PLC-gamma to catalyze 
phosphatidylinositol (4,5)-bisphosphate (PIP2) hydrolysis into inositol 1,4,5-triphosphate 
(IP3) and diacylglycerol (DAG). The latter product induces phosphorylation of protein 
kinase C (PKC), which also leads to activation of c-Raf-1 for ERK1/2 proliferation 
signaling. The third pathway, PI3K cascade, is important for lymphatic development as it 
regulates cell survival/ migration. Recruitment of PI3K activates this kinase to 
phosphorylate PIP2 into phosphatidylinositol (3,4,5)-triphosphate (PIP3). Thus, activated 
PIP3 binds and activates AKT, a regulator for cell survival. Through these signaling 
cascades, VEGFR3 facilitates LECs migration towards VEGFC-generating sources that 
contribute to the formation and remodeling of the lymphatic vasculature. 
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1.3.3 VEGFC processing and activity 
VEGFC is an indispensible growth factor for LEC proliferation and survival, as well as 
the development of the entire lymphatic vasculature. An important difference in the 
structure of VEGFC, unlike the other VEGF members (except for VEGFD), is the 
presence of additional N-terminal and C-terminal peptides flanking the VHD, which 
requires proteolytic processing during VEGFC synthesis. The previous in vitro VEGFC 
processing model indicates processed VEGFC can activate both angiogenic receptor 
(VEGFR2) and lymphatic receptor (VEGFR3); nevertheless, VEGFC in vivo signaling is 
lymphatic-specific (Joukov et al., 1997). This model does not address how VEGFC 
processing regulates it receptor affinity and activity in vivo. According to the in vitro 
VEGFC processing model, the ligand is initially synthesized as 61kDa  “Prepropeptide” 
containing signal peptide, N-terminal peptide (NT), VHD and C-terminal peptide (CT); 
then dimerizes through disulfide bonds between monomers’ flanking peptides (NT and 
CT), plus non-covalent interactions between two VHDs to give rise to 58kDa 
“Propeptide” dimer. The CT is cleaved off from propeptide monomers intracellularly by 
Furin and other protein convertases (Siegfried et al., 2003) and the partially processed 
ligands exit resident cells as "Pro-VEGFC". 
Once Pro-VEGFC reaches to the extracellular environment, another proteolytic cleavage 
occurs at the N-termini of each monomer to completely remove both NT and CT, thus 
resulting in 21kDa active form of VEGFC that activates both VEGFR2 and VEGFR3 in 
vitro. However, it is not yet clearly known the mechanism by which VEGFC is activated 
in vivo. Recently, Jeltsch et al. suggested that VEGFC activity in vitro is tightly regulated 
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by the activity of a secreted protein, CCBE1, and a metalloproteinase, ADAMTS3 
(Jeltsch et al., 2014). 
On the other hand, the VEGFC homolog, VEGFD, also undergoes proteolytic processing 
to become active (McColl et al., 2007). Since the loss of VEGFD does not result in 
lethality in mice, it is not yet known how VEGFD contributes to the lymphatic 
vasculature in vivo.  
 
Figure 8. Schematic of VEGFC proteolytic processing events. 
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1.4 Collagen and calcium-binding epidermal growth factor domain -1 (CCBE1) 
role in lymphangiogenesis 
1.4.1 The Hennekam’s syndrome and the secreted protein CCBE1 
Hennekam’s syndrome is a rare human autosomal recessive disorder characterized by 
malformation of the lymphatic vasculature. There are currently about 50 cases of 
Hennekam’s syndrome reported worldwide. The main characteristics of Hennekam’s 
syndrome are lymphatic vessels that are abnormally expanded (lymphangiectasia), tissue 
swelling caused by lymph trapping (lymphedema), and features of mental retardation 
(Fig. 9). Lymphangiectasia often prevents the flow of lymph fluid, causing the lymphatic 
vessels to rupture. The ruptured vessels can lead to accumulation of lymph fluid, which 
contributes to lymphedema. The lymphedema in Hennekam’s syndrome is often 
noticeable at birth and usually affects the face and limbs. Severely affected infants may 
have extensive swelling caused by fluid accumulation before birth. Hennekam patients 
often also have intellectual disabilities that range from mild to severe. In addition to those 
features, other abnormalities found in individuals with Hennekam’s syndrome include 
growth delay, respiratory problems, anemia, and so on. The signs and symptoms of 
Hennekam’s syndrome vary widely among affected individuals, even those within the 
same family. Life expectancy depends on the severity of the condition and can vary from 
death in childhood to survival into adulthood. 
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Figure 9. Examples of Hennekam patients (adapted from Alders et al., 2009). 
 
In 2009, our protein of interest, CCBE1, was found to associate with the human 
lymphedema-lymphangiectasia–mental retardation syndrome (Hennekam’s syndrome) 
(Alders et al., 2009). In fact, it was reported that approximately 23% of the Hennekam 
patients carry CCBE1 mutations in their genome (Fig. 10). The secreted protein CCBE1 
has since been intensively studied in both in vitro and in vivo contexts. 
 
Figure 10. Common mutations in CCBE1 from Hennekam patients (adapted from Alders et al., 2009) 
 
1274 VOLUME 41 | NUMBER 12 | DECEMBER 2009 NATURE GENETICS
does not exclude pathogenicity, as even if the mutant zebrafish protein 
has reduced activity, administration in excess by high-dose mRNA 
injection may still provide sufficient function to achieve rescue.
Mutations in CCBE1 are described here in a subset (5/22 = 23%) 
of families carrying Hennekam syndrome, indicating genetic 
heterogeneity. CCBE1 is not expressed in endothelial cells of lymph 
 vessels12, and it may be a component of the extracellular matrix. 
In zebrafish, ccbe1 expression was observed along the earliest migra-
tion routes of endothelial cells that sprout from the posterior cardinal 
vein and migrate circuitously before developing into lymphatic 
 vessels12,14. CCBE1 might therefore be involved in guidance of these 
migrating cells12. Ccbe1 is expressed in the developing mouse intestine 
(Supplementary Fig. 5), and we identified very few lymphatic vessels 
in intestinal biopsies from human subjects (Supplementary Fig. 6), 
consistent with a requirement for CCBE1 in lymphangiogenesis. 
Mutations in as-yet-unknown interaction partners of CCBE1 may 
cause a similar phenotype and are further candidate genes for this 
form of generalized lymphatic dysplasia in humans.
All subjects or their legal representatives provided informed 
consent to the study. The study was approved by the medical ethical 
committee of the Academic Medical Centre in Amsterdam. Written 
permission was obtained from the subjects or their legal represen-
tatives to publish clinical pictures.
Accession codes. GenBank: Homo sapiens CCBE1, NM_133459.1; 
Danio rerio ccbe1, NM_001163923.
Note: Supplementary information is available on the Nature Genetics website.
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Figure 2 Mutations in CCBE1 abolish normal gene function. (a) Locations 
of mutations in conserved amino acids in CCBE1. Information on domain 
localization was obtained from UniProt (http://www.uniprot.org).  
(b–j) Functional analysis of the mutations in the zebrafish ccbe1 model 
using the transgenic line TG(fli1a:gfp) y1, TG(kdr-l:ras-cherry)s916. Fli1a 
(green) is a marker for both blood and lymphatic endothelial cells, 
whereas Kdr-l (red) is expressed only in blood vessels12. (b,c) Injection 
of ccbe1 ATG-targeting morpholino (MO) (5 ng per embryo) led to a 
robust phenocopy of the ccbe1 mutant phenotype with absence (*) of 
the thoracic duct in injected (c) but not uninjected control (b) embryos 5 d postfertilization. (d–i) The ccbe1 ATG MO phenotype is robustly rescued by 
injection of wild-type ccbe1 mRNA (d) but not mRNA encoding the C67S (e), C94S (f), C166R (h) or G313R (i) substitutions. The mRNA encoding  
the R150C substitution was capable of rescue (g). Asterisk, lack of rescue; arrows, thoracic duct. mRNAs were all injected at 350 pg per embryo.  
(j) Summary of rescue experiments. Embryos were scored for the presence or absence of the thoracic duct (TD), and data are shown for uninjected control 
(100% TD+, n = 21 embryos scored), MO injected (6% TD+, n = 75), MO + ccbe1 mRNA (97% TD+, n = 117), MO + ccbe1 C67S mRNA (25% TD+,  
n = 108), MO + ccbe1 C94S mRNA (4% TD+, n = 96), MO + ccbe1 R150C mRNA (78% TD+, n = 57), MO + ccbe1 C166R mRNA (0% TD+, n = 87) and 
MO + ccbe1 G313R mRNA (0% TD+, n = 73). The mutations in e–i are equivalent to human C75S, C102S, R158C, C174R and G327R, respectively.
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Figure 1 Phenotypes of subjects with generalized lymphatic dysplasia and homozygosity mapping in five subjects with consanguineous parents.  
(a) Subject D, with flat face, hypertelorism and flat nasal bridge. (b) Subject G, with widespread congenital lymphedema and distended abdomen due 
to ascites. (c,d) Subject F, showing webbing of the neck as result of intrauterine lymphedema, limb lymphedema, distended abdomen due to ascites, 
and muscle wasting at 20 years. (e) Distended lymph vessels in the intestinal wall of subject F (see also Supplementary Fig. 6). (f) Uneven endothelial 
podoplanin staining in lymphangiectasia (small intestine, subject F). (g) Pedigrees of the subjects with consanguineous parents. Affected subjects are 
shown as filled circles (females) or squares (males). All parents tested were heterozygous carriers (dot). (h) Homozygous regions at chromosome 18q21, 
indicating a shared homozygous region of 0.5 Mb. Bars, homozygous segments; flanking SNPs are indicated.
C174R are in the calcium-binding EGF domain, the first introducing 
an extra cysteine that might interfere with proper folding of the pro-
tein and the second disrupting a conserved cysteine residue predicted 
to form disulfide bonds important for the secondary structure of this 
domain (Fig. 2a). All mutations were absent in controls of Western 
European (n = 100) or Arabic (to match the ethnic background of 
subject D; n = 97) descent. None of the other subjects from 17 families 
carrying Hennekam syndrome harbored a CCBE1 mutation.
The function of ccbe1 (ref. 12) h s bee  studied in a zebrafish lymph-
angiogenesis model14,15. Zebrafish ccbe1 mutants lack parachordal 
lymphangioblasts and all known lymphatic vessels. Mutants develop 
lymphedema but retain a largely normal cardiovascular system. Wild-
type ccbe1 mRNA rescues the mutant12 and morpholino-induced 
knockdown (morphant) phenotypes, whereas mutant mRNA does 
not. Therefore this model is suitable for testing pathogenicity of 
missense mutations identified in this study.
We introduced homologous mutations in zebrafish ccbe1 and 
tested the ability to rescue the ccbe1 morphant phenotype (Fig. 2b–i). 
Injection of wild-type ccbe1 mRNA reliably rescued the absence of the 
thoracic duct (Fig. 2b–d,j). Three of the five mutant mRNAs tested 
(C94S, C166R and G313R, equivalent to human C102S, C174R and 
G327R, respectively) were not able to confer any rescue (Fig. 2f,h–j; 
Supplementary Fig. 4). Mutant C67S (equivalent to human C75S) 
showed weak rescue, and R150C (equivalent to human R158C) more 
robust rescue comparable to that seen with wild type (Fig. 2e,g,j), indi-
cating that at least some mutant protein function was preserved. This 
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1.4.2 The potential role of CCBE1 in lymphangiogenesis 
CCBE1 is a secreted protein that is 407AA, including a N-terminal calcium-binding 
EGF-like domain and a C-terminal collagen-like assembly of GPP repeats. CCBE1 was 
first described in zebrafish as an indispensible factor for embryonic lymphangiogenesis 
as homozygous mutation of this protein leads to lack of parachordal lymphangioblasts 
and lymphatic vessels (Hogan et al., 2009; Küchler et al., 2006). Homozygous Ccbe1-
deficient mice fails to form lymphatic vessels from E13.5 onwards (Yang et al., 2012; 
Oliver, 2004; Bos et al., 2011), thus leading to lymphedema and LEC progenitors 
impaired migration from CV.  
Despite its identical loss-of-function phenotype to mice lacking of the lymphangiogenic 
factor VEGFC, CCBE1 was initially proposed to be independent of VEGFC/ VEGFR3 
pathway by Bos et al. (2011). However, in 2014, Le Guen et al. reported that zebrafish 
CCBE1 regulates VEGFC/ VEGFR3-induced embryonic lymphangiogenesis using 
immunofluorescence visualization of phosphorylated ERK in the posterior cardinal vein 
(Le Guen et al., 2014). Interestingly, in this report, CCBE1 was suggested to be involved 
in the post-translational activation of VEGFC, specifically the proteolytic cleavage at the 
N-terminus of Pro-VEGFC ligand. As CCBE1 is not a protease, the question of which 
protease is responsible for processing VEGFC’s N-terminus becomes intriguing. Jeltsch 
et al. proposed that the metalloproteinase ADAMTS3 is the potential candidate that 
cleaves VEGFC in vitro (Jeltsch et al., 2014). Nevertheless, a clear molecular 
understanding of these events has not yet emerged because of the difficulties in following 
VEGFC proteolysis, assessing its role in LEC responses ex vivo and in vivo, and lack of 
evidences supporting a role of ADAMTS3 in lymphangiogenesis. The former is due to 
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the fact that many studies have used VEGFR3 ectodomain pull-down approach, which is 
biased toward detection of VEGFR3-binding VEGFC proteins, and limits to the role of 
cell-surface-associated VEGFC activation. The latter, i.e. if ADAMT3 had an 
indispensable role in lymphangiogenesis in vivo, was not yet known at the beginning of 
this thesis. As a result, this thesis utilizes different approaches to avoid such bias and 
limitations, while addressing this question. 
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1.5 The A Disintegrin and Metalloproteinase with Thrombospondin motifs 
(ADAMTS) family and ADAMTS3 
1.5.1 The ADAMTS family 
The human ADAMTS family consists of 19 zinc-dependent metalloproteinases that have 
various roles in the regulation of tissue morphogenesis/ remodeling, inflammation and 
angiogenesis. In general, genetic mutations in certain ADAMTS family members are the 
causes of inherited genetic disorders, whereas defects in expressing others are linked to 
arthritis, cancer and other cardiovascular diseases (reviewed in Kelwick et al., 2015). 
The basic structure of ADAMTSs is organized into a pro-domain, a catalytic domain, and 
an ancillary domain. The pro-domain of ADAMTSs not only maintains latency of pro-
ADAMTSs, but also assures proper enzyme folding. It has been reported that the pro-
domain is removed at R/KXnR/K sites by furin and furin-like pro-protein convertases 
(PPCs) (Wang et al., 2004; Longpre et al., 2009). Moreover, the catalytic domain 
consists of the metalloproteinase domain, in which three histidine residues coordinate a 
Zn2+ ion that determines the enzyme activity (Gomis-Ruth, 2009), and the disintegrin-like 
domain. The crystal structure for ADAMTS1, ADAMTS4, and ADAMTS5 revealed that 
the disintegrin-like domain is a cysteine-rich region stacking against the 
metalloproteinase site, thus making it part of the catalytic domain (Gerhardt et al., 2007; 
Mosyak et al., 2008). Furthermore, the carboxyl-terminal ancillary domains of 
ADAMTSs have been suggested to determine enzyme localization and substrate 
specificity.  The ancillary domain in ADAMTS enzymes contains a thrombospondin 1-
like repeat (TSP1), followed by a cysteine-rich region and a variable cysteine-free spacer 
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region, and finally a variable number of TSP1 domains, except for ADAMTS4 that has 
none.  
 
 
 
 
 
 
 
 
 
 
Figure 11. Structure of ADAMTS family members (adapted from Kelwick et al., 2015). 
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1.5.2 The ADAMTS functional group in lymphangiogenesis 
The members of ADAMTS family can be sub-grouped on the basis of their known 
substrates: the aggrecanases or proteoglycanases (ADAMTS1, 4, 5, 8, 9, 15 and 20), the 
cartilage oligometric matrix protein-cleaving enzymes (ADAMTS7 and 12), the von-
Willebrand Factor proteinase (ADAMTS13), and the procollagen N-propeptidases 
(ADAMTS2, 3 and 14). Other ADAMTSs (like ADAMTS6, 10, 16, 17, 18, and 19), the 
substrate of which is unknown, remain uncategorized. Most of the ADAMTS proteases 
have not been reported to participate in lymphangiogenesis, except for ADAMTS3 that 
belongs to the procollagen N-propeptidases subgroup (Jeltsch et al., 2014). 
ADAMTS2, 3 and 14 have been identified to be the major proteases involved in collagen 
fibril maturation. Ehler-Danlos’s syndrome (EDS) type VIIc is an inherited connective 
tissue disorder, which is caused by a defect in the processing and maturation of collagen. 
As maturation of collagen fibrils is essential to assure tissue physical strength and 
morphologies, patients with EDS type VIIc present several phenotypes including severe 
skin fragility, depressed nasal bridges, micrognathia and short stature (Cabral et al., 
2005). In the context of EDS type VIIc, ADAMTS-2 is the most important pro-collagen 
peptidase. Several mutations in ADAMTS-2 have been described and are associated with 
EDS type VIIc (Colige et al., 2004). The Adamts2-/- mice, despite surviving to birth, show 
defects in procollagen processing, abnormal lungs and fragile skin (Le Goff et al., 2006). 
This demonstrates that ADAMTS3 and 14 are not sufficient to compensate for the loss of 
ADAMTS2 in the skin. However, at the beginning of this thesis, the phenotype that is 
caused by loss of the other two members, particularly ADAMTS3 had not been 
identified.  Therefore, the study of ADAMTS3 activity and functions in this thesis would 
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provide a novel insight into the importance of this protein, which has not been 
appreciated in the past.  
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1.6 Project hypothesis and thesis aims 
Hypothesis: Proteolytic activation by ADAMTS3 defines distinct mechanisms of 
lymphangiogenesis mediated by VEGFC and VEGFD. 
Recent studies have implicated CCBE1 and ADAMTS3 in the regulation of VEGFC 
processing, and generated a model of lymphangiogenesis in which VEGFR3-bound 
VEGFC is cleaved by CCBE1 and ADAMTS3 during receptor activation (Jetlsch et al., 
2014). These studies have linked CCBE1 and ADAMTS3 to VEGFC function; but 
limitations in the biochemical analysis of VEGFC and VEGFD proteolytic processing, a 
lack of clear correlation between in vitro and in vivo studies, and lack of in vivo evidence 
for the role of ADAMTS3 have limited the understanding of this complex 
lymphangiogenic process. In addition, the structures of VEGFC and VEGFD are distinct 
from those of other VEGF members, in which they contain N-terminal and C-terminal 
domains that are proteolytically cleaved. The proteolytic processing of VEGFC and 
VEGFD is thought to regulate lymphatic vessel growth, but precisely how this processing 
is achieved and controlled in vivo has not been clear. In this thesis, an array of novel 
biochemical, cellular and mouse genetic approaches will be used to dissect and 
understand the relationships between CCBE1, ADAMTS3 and the lymphangiogenic 
factors VEGFC and VEGFD: 
 
1. To biochemically follow VEGFC and VEGFD proteolytic processing by 
inserting an epitope (FLAG) tag into the mature forms of these proteins 
that does not interfere with proteolysis or VEGFR3 activation.  
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2. To test the role of ADAMTS3 in VEGFC and VEGFD processing ex vivo 
using CRISPR/Cas9 genome editing to mutate the ADAMTS3 gene in 
HEK293 cells.  
3. To determine whether and to what extent these biochemical and ex vivo 
cellular findings predict in vivo lymphangiogenic responses by: 
a. Examining lymphatic development in ADAMTS3-deficient 
embryos. 
b. Analyzing the lymphangiogenic responses induced by either 
VEGFC or VEGFD in adult CCBE1-deficient mice.  
 
 
Predictions: 
The hypothesis supports a mechanism in which CCBE1 functions as an activator of the 
ADAMTS3 protease that cleaves the N-terminus of VEGFC. N-terminal cleavage of 
VEGFC by CCBE1 and ADAMTS3 is independent of the VEGFR3 receptor, but is 
required for VEGFC to stimulate VEGFR3 signaling. Consistent with this molecular 
model, embryonic ADAMTS3 deficiency should result in a complete loss of lymphatic 
development in mice, a phenotype also observed with loss of either CCBE1 or VEGFC. 
In contrast, it is expected that VEGFD processing is not regulated by either CCBE1 or 
ADAMTS3 in vitro, and CCBE1-deficient animals exhibit normal lymphangiogenic 
responses to VEGFD in vivo. Thus, these studies would demonstrate distinct mechanisms 
of proteolytic activation for VEGFC and VEGFD that help explain their distinct roles in 
prenatal and postnatal lymphatic vascular growth. 
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CHAPTER TWO 
 Materials and Methods 
 
Cell culture 
HEK293T cell line (Invitrogen) and its derivatives (e.g. CRIPSR/Cas9 engineered 
HEK293T cells) were maintained in DMEM with 10% FBS (Corning #35-010-CV) and 
100 µg/mL Penicillin-Streptomycin (Invitrogen #15070063). All cell cultures were grown 
at 37oC and 5% CO2 incubators.  
Generation of epitope-tagged VEGFC, CCBE1, and ADAMTS3 proteins 
Full-length human cDNAs for VEGFC, VEGFD, CCBE1, and ADAMTS3 were obtained 
from GE Dharmacon (Lafayette, CO).  Epitope-tagged cDNAs were generated through 
PCR amplification using primers containing in-frame V5, Flag, or HA tags.  All final 
constructs were confirmed by nucleotide sequencing.  Primers used are as follow: 
CCBE1-V5 
Forward - TCT AGA TCT GCT TCC CTG ATG GTG CCG 
Reverse - AAG CGG CCG CTT AGG TGC TAT CCA GGC CCA GCA GCG GGT 
TCG GGA TCG GCT TGC CTG GGT AGA AGT CTC TGG GGG CTC 
 
CCBE11-175-V5 
Forward - TCT AGA TCT GCT TCC CTG ATG GTG CCG 
Reverse - AAG CGG CCG CTT AAT GAT GAT GAT GGT GGT GGG TGC TAT 
CCA GGC CCA GCA GCG GGT TCG GGA TCG GCT TGC CGG ATTG GAA 
GTA CAG GTT CTC GGT ACA TGT CTT 
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VEGFC-V5 
Forward - TCT GGA TCC GGT ACC CGG TCC TTC CAC CAT GCA CTT GCT 
GGG 
Reverse - AAG CGG CCG CTT AGG TGC TAT CCA GGC CCA GCA GCG GGT 
TCG GGA TCG GCT TGC CGG CGC TCA TTT GTG G 
 
VEGFCΔC-flag-V5 
Forward - TCT GGA TCC GGT ACC CGG TCC TTC CAC CAT GCA CTT GCT 
GGG 
Reverse - AAG CGG CCG CTT AGG TGC TAT CCA GGC CCA GCA GCG GGT 
TCG GGA TCG GCT TGC CCT TGT CAT CGT CGT CCT TGT AGT CAC GTC 
TAA TAA TGG AAT GAA CTT GTC 
 
VEGFCΔNΔC  
Forward - TAG GAT CCG CCA CCA TGG AGA CAG ACA CAC TCC TGC TAT 
GGG TAC TGC TGC TCT GGG TTC CAG GTT CCA CTG GTA CAG AAG AGA 
CTA TAA AAT TTG C 
Reverse - AAG CGG CCG CTT AAC GTC TAA TAA TGG AAT GAA CTT GTC 
 
VEGFC-VHD-flag 
Reverse (of the N-terminal portion) – GGA TCC CTT GTC ATC GTC GTC CTT 
GTA GTC AAC TTG TCT GTA AAC ATC C 
Forward (of the C-terminal portion) - GGA TCC CAT TCC ATT ATT AGA CGT 
TCC 
 
VEGFD-VHD-flag 
Forward - CCA TAC TCA ATT ATC AGC AGC TCC ATC CAG ATC CCT GAA 
G  
Reverse - C TTC AGG GAT CTG GAT GGA GCT GCT GAT AAT TGA GTA 
TGG 
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ADAMTS3-V5 
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G 
Reverse - AAG CGG CCG CTC AGG TGC TAT CCA GGC CCA GCA GCG GGT 
TCG GGA TCG GCT TGC CTC TTT CTA AGG TGG A 
 
ADAMTS3-HA 
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G  
Reverse - AAG CGG CCG CTC AAG CGT AAT CTG GAA CAT CGT ATG GGT 
ATC TTT CTA AGG TGG A 
 
ADAMTS3ΔCT-HA 
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G  
Reverse - AAG CGG CCG CTC AAG CGT AAT CTG GAA CAT CGT ATG GGT 
AAC AAG GAG GCA GTT G 
 
ADAMTS3Δ3TSP-HA 
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G  
Reverse - AAG CGG CCG CTC AAG CGT AAT CTG GAA CAT CGT ATG GGT 
AAT GGA TGA TGT ACT T 
 
ADAMTS3ΔSpacer-HA 
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G  
Reverse - AAG CGG CCG CTC AAG CGT AAT CTG GAA CAT CGT ATG GGT 
AGC AGT GGG AAT TAT CTC CTC 
 
ADAMTS3ΔCys-tich-HA 
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G  
Reverse -  AAG CGG CCG CTC AAG CGT AAT CTG GAA CAT CGT ATG GGT 
AGC ATT CTT CTG TGT TAC AAA 
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ADAMTS3Δ4TSP-HA 
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G  
Reverse -  AAG CGG CCG CTC AAG CGT AAT CTG GAA CAT CGT ATG GGT 
AAT TGC CAT CTT GTT TTT GCT 
 
ADAMTS3ΔDisintegrin-HA 
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G  
Reverse -  AAG CGG CCG CTC AAG CGT AAT CTG GAA CAT CGT ATG GGT 
AAA GGA GAC AGT CAT AGG AAT 
 
Point mutations in CCBE1 and VEGFC were generated using the QuikChange II Site-
Directed Mutagenesis Kit (Agilent Technologies #200523).  The procedure was carried 
out according to manufacturers’ guidelines. All final constructs were confirmed by 
nucleotide sequencing.  Mutagenesis primers used are as follow: 
 
VEGFC-RR226,227SS 
Forward - CAA GTT CAT TCC ATT ATT TCC TCC TCC CTG CCA GCA ACG 
TTA  
Reverse - TAA CGT TGC TGG CAG GGA GGA GGA AAT AAT GGA ATG 
AAC TTG 
 
VEGFC-LTTTF 
Mutagenesis step 1:  
Forward - ACT ATA AAA TTT GCT GCA ACG TTC TAT AAT ACA GAG ATC 
TTG LEC  
Reverse - CAA GAT CTC TGT ATT ATA GAA CGT TGC AGC AAA TTT TAT 
AGT 
33 
Mutagenesis step 2 
Forward - ACA GAA GAG ACT ATA AAA TTG ACT ACA ACG TTC TAT AAT 
ACA GAG 
Reverse - CTC TGT ATT ATA GAA CGT TGT AGT CAA TTT TAT AGT CTC 
TTC TGT 
 
CCBE1D170E 
Forward - CAT CCG GGA AGA TGA AGG GAA GAC ATG TAC CCG GGG 
AGA CAA ATA TCC 
Reverse - GTA GGC CCT TCT ACT TCC CTT CTG TAC ATG GGC CCC TCT 
GTT TAT AGG 
 
Protein expression and characterization 
Epitope-tagged cDNA constructs were cloned into pcDNA 3.1+ and transfected into 
wild-type HEK293T cells or mutant HEK 293T lines where indicated.  Cells were plated 
at density of 3x105 cells/10 cm2 and transfected using Lipofectamine 2000 in 1:6 ratio 
(Invitrogen #11668019).  Unless otherwise indicated, conditioned media were collected 
72 hours after transfection.  Conditioned supernatants were mixed at a 1:1 ratio unless 
otherwise indicated and incubated for 18 hours at 37oC prior to analysis. Untransfected 
HEK293T conditioned media (CM) was collected and used as control supernatant.  
 
Western Blotting  
Supernatant samples from CM mixings were loaded and run on SDS–polyacrylamide gel 
electrophoresis (PAGE) 12% gradient gel (BioRad, Carlsbad, CA) as soon as mixing was 
complete, then transferred onto PVDF membrane. Whole-cell protein extracts were 
34 
prepared by addition of RIPA lysis buffer (25 mM Tris.HCl pH 7.6, 150 mM NaCl, 1% 
NP-40, 1% sodium deoxycholate, 0.1% SDS, and complete protease inhibitors (Roche 
#4693159001). Lysates were separated by SDS–polyacrylamide gel electrophoresis 
(PAGE) on a 4% to 12% gradient gel and transferred to PVDF membrane. Western 
blotting was probed with anti-V5-HRP (1:5000, Invitrogen #46-0708), anti-Flag-HRP 
(1:2500, Sigma #A8592-1MG), and anti-HA (1:10000, Biolegend #MMS-101P-500) 
antibodies. All HRP-conjugated antibody blots were developed using ECL reagent 
(Invitrogen). HRP-conjugated goat anti-mouse or anti-rabbit IgG antibody (1:10000; 
Jackson Immunoresearch) was used as secondary antibody for detection.  
 
Post-translational modification of CCBE1 
CCBE1-V5 was transfected into HEK293T cells and collected after 72 hours. 
Supernatants of CCBE1-V5 were treated with Heparinase (Sigma #H2519), 
Chondroitinase (Sigma #C3667), PNGase F (Sigma #P7367), and O-glycosidase (Sigma 
# G1163) for 1 hour at 37oC. Final products were analyzed by Western blotting.  
 
Phospho-VEGFR3 ELISA assay  
Neonatal lymphatic endothelial cells were obtained from Lonza (#CC-2543) and used 
between passage 6 and 8.  LECs were plated on 6-well plates (density = 3x105 cells/10 
cm2), and starved with 900 µl starving media [EBM2 media (Lonza #CC-3156) + 0.1% 
BSA (Sigma #A1595)] for 6 hours at 37oC. Serum starved LECs were treated with 100 µl 
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of the indicated conditioned media for 15 minutes at 37oC. The media was then aspirated 
and the cells washed three times with cold PBS before being lysed with 150 µl of 
Phospho-VEGFR3 lysis buffer (1% NP-40 Alternative, 20 mM Tris (pH 8.0), 137 mM 
NaCl, 10% glycerol, 2 mM EDTA, 1mM activated sodium orthovanadate, 10% protease 
inhibitors). Samples were collected and the following steps were complied with 
instructions in Human Phospho-VEGFR3 ELISA kit (R&D #DYC2724-5).  
 
Immunoprecipitation 
Conditioned supernatants were harvested (after 72h transfection) and mixed for 18 hours 
at 4oC before adding anti-V5-tag magnetic beads (MBL #	  M167-11). The magnetic beads 
were then incubated with final mix for 6 hours at indicated conditions (4oC or 37oC or 
addition of EDTA). Beads were washed three times using Optimem 1x (Invitrogen #	  
31985062) and bound proteins then eluted in 4x sample buffer (Invitrogen #	  NP0007) and 
analyzed by Western blotting. 
 
CRISPR/Cas9 generation of ADAMTS3-deficient and CCBE1-deficient HEK293T 
cells 
Guide RNAs (5’-CACCGTTGGTTGATAGCAGCCGCTC-3’) targeting the signal peptide 
of ADAMTS3 were cloned into the pSpCas9 (BB)-2A-Puro (PX459) V2.0 plasmid 
(Addgene). The resulting plasmids were then transfected into HEK293T cells on 6-well 
plates using the FuGENE6 (Promega #E2691) reagent and standard protocols. The 
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transfected cells were then selected by addition of puromycin to the media between 12 
and 36 hours post-transfection, and the selected cells were then clonally diluted onto 96 
well plates.  After two weeks of growth, wells with single colonies were identified and 
subsequently expanded.  For each of these HEK293T clones, the targeted region of the 
ADAMTS3 gene was then amplified by PCR, and individual PCR products were isolated 
by TA cloning (T-easy vector, Invitrogen #A1380).  A sample of the amplified 
ADAMTS3 alleles present in each cell line was obtained by sequencing at least 10 
different TA-cloned PCR products from each line.  
In the same approach as mentioned above, CCBE1-deficient HEK293T clones were 
generated, selected, expanded, and extracted for sequencing.   
CCBE1 gRNA (CRISPR): 5’- CACCGTCCACGTGTGTCCCAACGCC -3’ 
 
Plasmin activity assay 
VEGFC-VHD-flag and VEGFD-VHD-flag were transfected into ADAMTS3-deficient 
HEK293T cells, and collected supernatants after 72 hours. Supernatants CMs were 
treated with plasmin (HTI #HCPM-0140) at 37oC, and final products were analyzed by 
Western blotting. 
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Mouse lines  
Ccbe1 null and conditional alleles were generated and previously reported (Zou et al., 
2013). The Ccbe1 gene was disrupted in SV129 embryonic stem (ES) cells by replacing 
the coding portion of exon 3 with a gene-trap cassette containing a splice acceptor IRES-
β polyA and an FRT-flanked neomycin resistance cassette (L1L2_Bact_P). A conditional 
allele was generated by replacing exon 3 with a loxP-flanked exon 3 cassette. Correctly 
targeted ES cells were injected into blastocysts and chimeric offspring were crossed with 
SV129 and C57Bl/6 mice. Prox1-GFP, Ccbe1 animals were generated by crossing Ccbe1 
with Prox1-GFP animals (Choi et al., 2011). Adult VEGFC Knock-Out (KO) and 
VEGFD KO mice have been previously described (Nurmi et al., 2015; Baldwin et al., 
2005). The Ub-CreERT2 allele was obtained from Jackson Labs (#70017).  The Adamts3 
targeted mice were obtained from Adamts3tm1a(KOMP)Wtsi, clone ID EDP0660_2_C10 sperm from 
the KOMP repository (http://www.komp.org). Adamts3 null mice generated by crossing 
Adamts3tm1a(KOMP)Wtsi, clone ID EDP0660_2_C10 and EIIa-Cre animals (Jackson labs #003724). 
Neonatal and adult deletions were induced by administration of tamoxifen. A total of 0.1 
mL of 20 mg/mL tamoxifen in sunflower oil was injected intraperitoneally daily for 14 
days to induce deletion in adult Ub-CreERT2;Ccbe1flox/lacZ mice. Adult animals were 
maintained on tamoxifen chow for more than 6 weeks prior to in vivo studies to ensure a 
high deficiency state. 
The University of Pennsylvania Institutional Animal Care and Use Committee approved 
all animal protocols. 
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Whole-mount microscopy  
Imaging of ear lymphatics was performed after manual splitting of the ear leaflets 
performed after a one-hour incubation in PBS. For whole-mount immunostaining, ear 
leaflets were fixed overnight in 4% paraformaldehyde at 4oC. Tissue was permeabilized 
in TBS plus Triton X-100, and stained overnight with anti-LYVE1 (R&D) antibodies, 
and detected using secondary antibody conjugated to Alexa-568. 
 
Viral expression of VEGFC in vivo 
Cutaneous adenoviral expression: 2 x 108 - 2 x 109 PFU of adeno-VEGFC or control 
adenovirus expressing either VEGFB or GFP were injected subcutaneously in the dorsal 
skin of adult mice. 1 x108 PFU of adeno-mCherry was co-injected to identify the site of 
expression prior to skin harvest.  After 48h, BrdU was injected intraperitoneally 24h prior 
to harvest to label proliferating cells.  
Muscular adeno-associated viral expression: AAV9 constructs containing murine full-
length VEGFC, VEGFCΔNΔC or VEGFD were used (Anisimov et al., 2009). 9-12 x 1010 
viral particles mixed with AAV9-mCherry was injected into the left tibalis anterior and/or 
gastrocnemius muscles.  Muscles were harvested 4 weeks after injection for histologic 
analysis of lymphatic growth. 
The viruses were provided by the Alitalo lab (University of Helsinki, Finland) and also as 
a kind gift from Dr. Calvin Kuo (Stanford University, Palo Alto, CA). 
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Histologic analysis 
Mouse embryos and tissues were fixed in 2% paraformaldehyde for 24hours, dehydrated 
in 100% ethanol, and embedded in paraffin. Serial 6 µm-thick sections were subjected to 
hematoxylin and eosin (H&E) or immuno-histochemical staining. Immunofluorescence 
was performed with polyclonal anti-mouse antibodies for PROX1 (Abcam #76696), and 
LYVE-1 (R&D #AF2125), VEGFR3 (R&D #AF743), PECAM (R&D #MAB3628), 
FLK-1 (BD Biosciences #555307), K14 (Covance #PRB-155P) or BrdU (Abcam 
#ab6326).   
Images were acquired with a Nikon Eclipse 80i microscope using a 20x/0.50 or 40x/0.75 
numeric aperture (NA) dry objective.  
 
The peritoneal inflammatory assay 
Experimental animals were injected with 25 µg LPS (Escherichia coli 0111:B4; Sigma- 
Aldrich) in 200µl PBS for the first two days, allowed mice to recover for the next two 
days, and continued for four consecutive days with a daily dose of 12.5 µg LPS in 200µl 
PBS. Necropsy was performed on day nine; diaphragms were fixed in 4% PFA overnight 
in cold and stained for LYVE1 (R&D) using a standard whole mount protocol. Images 
were acquired using AzioZoomV16 microscope equipped with Orca Flash 4 camera and 
LYVE1 area was quantified using ImageJ. Brush painting of the LYVE1 lymphatic 
vessels was used to improve the contrast and the accuracy of quantification. 
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The full thickness excision assay 
16-week C57Bl/6 mice (approximately 20g) were injected with Buprenorphine (0.5-1 
mg/kg) analgesia and anesthetized using Isoflurane (5% Isoflurane in 1L/min Oxygen). 
Once mice are anesthetized, they will be transferred to a nose cone with 1% Isoflurane 
and 1L/min Oxygen. The pedal (paw pinch) reflex will be used to determine the depth of 
anesthesia. Back hair was clipped off each mouse using clippers. Iodine was applied to 
the rear dorsum to prevent injection during surgery and cleaned by alcohol pad. Blunt-
tipped scissors and curved forceps were used to remove a 1.5cm x 1.5cm area of skin 
down to but not including the muscle layer. Mice were daily observed after surgery and 
harvested at indicated time. Newly healed skin samples were processed and analyzed by 
immunohistochemistry using PROX1 (Abcam) and LYVE1 (R&D) antibodies.  High-
power field images were acquired with a Nikon Eclipse 80i microscope (40 fields per 
skin sample), and number of lymphatic (PROX1+ LYVE1+) vessels and PROX1+ nuclei 
were counted.  
 
Statistical Analysis 
All error bars indicate standard error of the mean (SEM). Unpaired, two-tailed student’s 
T-test was applied to all indicated samples.  A P value less than 0.01 was considered 
significant. 
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CHAPTER THREE 
CCBE1 drives N-terminal cleavage that is independent of both C-terminal cleavage 
and VEGFR3 interaction capabilities of VEGFC 
3.1 Rationale 
Most previous studies of VEGFC and VEGFD proteolytic processing have been 
performed using VEGFR3 ectodomain pull-down of metabolically labeled proteins to 
identify the different species of these secreted growth factors. This approach has 
successfully demonstrated post-translational proteolysis of these proteins, but detection 
based on VEGFR3 binding may bias protein detection because VEGFC and VEGFD 
proteins bind more weakly than processed proteins to VEGFR2 and VEGFR3 receptors. 
VEGFC processing is believed to involve two distinct proteolytic events that combine to 
release a central peptide that is homologous to VEGFA termed the VEGF homology 
domain (VHD). To follow VEGFC processing in a direct and unbiased manner, we 
introduced a FLAG epitope into the C-terminal end of the VEGFC-VHD immediately 
adjacent to the well-characterized site of C-terminal cleavage. To further follow 
proteolytic processing using VEGFC VHD-FLAG, we first generated a VEGFC VHD-
FLAG that also contains an HA tag fused in frame to the end of the VEGFC C-terminus 
(CT). We could then study the relationship between VEGFC cleavage and its activity by 
measuring the level of VEGFR3 phosphorylation and identifying the cleavage site. By 
mutating specific amino acids within the cleavage site, we were able to manipulate 
VEGFC N-terminal cleavage to answer the question how crucial the proteolytic 
processing is for VEGFC activation.  
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3.2 Detection of VEGFC processing in vitro 
Immunoblot analysis for FLAG in the conditioned medium of HEK293 cells that express 
VEGFC VHD-FLAG CT-HA (Fig. 12A) revealed a dominant ∼35 kDa band under 
reduced conditions, consistent with a peptide containing the N-terminus (NT) and VHD 
domains of VEGFC. Anti-FLAG immunostaining under non-reduced conditions revealed 
a strong 58-60 kDa band (Fig. 12B). Anti-HA immunostaining of the same blot revealed 
a 28 kDa band under reduced conditions, consistent with the isolated CT, and a 58-60 
kDa band identical to that observed with anti-FLAG antibodies under non-reduced 
conditions, indicating that the 58-60 kDa band most likely represents NT-VHD-FLAG 
and CT-HA peptides bound together by disulfide bonds. 
 
 
 
 
Figure 12. Expression of VEGFC VHD-FLAG in vitro. (A) Schematic of the VEGFC VHD-FLAG 
protein in which a FLAG epitope is inserted in frame at the C terminal end of the VHD. Disulfide 
bonds are predicted to link two full-length VEGFC VHD-FLAG molecules as shown below. (B) 
Detection of VEGFC-VHD-FLAG with a C-terminal HA tag is shown under reduced and non-reduced 
conditions using anti-FLAG (left) and anti-HA (right) antibodies. NT, amino terminus; VHD, VEGF 
homology domain; CT, carboxyl terminus. The VEGFC VHD-FLAG construct was designed by Dr. 
David Enis.  
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3.3 CCBE1 full-length drives VEGFC N-terminal cleavage in a time-dependent 
manner 
To test the effect of CCBE1 on VEGFC processing, we incubated VEGFC VHD-FLAG 
with CCBE1-V5 by mixing conditioned supernatants of HEK293T cells. Incubation of 
VEGFC with CCBE1 resulted in the generation of a single 19-21 kDa protein containing 
the VEGFC VHD at 370C but not 40C. This result was consistent with the notion that the 
NT cleavage of VEGFC correlates with enzymatic activity, which is temperature 
dependent. Timed analysis of mixed supernatants incubated at 370C for 0-18 hours 
revealed progressive cleavage of VEGFC VHD-FLAG with complete processing by 18 
hours (Fig. 13). In this assay, we were able not only to demonstrate CCBE1 facilitates 
VEGFC processing at its NT, but also to design a standard protocol to study VEGFC 
proteolysis in vitro. 
 
  
 
 
 
 
 
Figure 13. Full length CCBE1 drives VEGFC proteolysis in vitro. (A) HEK293T conditioned media 
containing VEGFC VHD-FLAG alone or VEGFCVHD- FLAG + CCBE1-V5 were incubated for 24 
hours at 40C or 370C prior to detection of FLAG by immunoblot analysis. (B) Temporal analysis 
reveals slow proteolysis of VEGFC in the presence of CCBE1. NT, amino terminus; VHD, VEGF 
homology domain. 
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Previous studies of VEGFC processing following protein expression by HEK293 and 
other cell types have suggested that C-terminal cleavage after amino acid R227 occurs 
prior to N-terminal cleavage and is highly efficient. To determine whether CCBE1-driven 
NT cleavage requires prior CT cleavage, we examined the effect of CCBE1 on VEGFC 
RR226/227SS-HA, a mutant in which the CT is not cleaved and the protein is C-terminally 
tagged. VEGFC RR226/227SS-V5 (VEGFC CT uncleavable) was detected as a 58 kDa 
protein that is consistent with a full length VEGFC protein containing the NT, VHD and 
CT domains (Fig. 14). Following exposure to CCBE1, anti-V5 immunostaining identified 
a 45kDa protein that is consistent with the VEGFC VHD and CT domains. These 
findings demonstrate that CCBE1 drives N-terminal VEGFC proteolysis that is 
independent of its processing at the CT cleavage site. Importantly, they also demonstrate 
that CCBE1 regulation of VEGFC processing does not require interaction with LECs or 
the VEGFR3 receptor conditions. 
 
 
 
 
 
 
Figure 14. N terminal cleavage of VEGFC is independent of C terminal cleavage. A VEGFC VHD-
FLAG protein containing a mutation that prevents C terminal cleavage (RR226-227SS) was incubated 
with CCBE1-V5 or control conditioned medium for 24 hours. NT, amino terminus; VHD, VEGF 
homology domain; CT, carboxyl terminus. 
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3.4 The CCBE1 N-terminal domain does not support VEGFC processing 
Since full length CCBE1 is difficult to express, previous studies have investigated 
CCBE1 function using a truncated protein that contains only the N-terminal domain, e.g. 
CCBE1 175 (Roukens et al., 2015). To directly test the function of such truncated 
CCBE1 proteins, we expressed VEGFC VHD-FLAG and full length CCBE1-V5 or 
CCBE1 175-V5 in HEK293T cells. Mixing of conditioned media revealed no effect of 
CCBE1 175 on the processing of VEGFC under these in vitro conditions, despite the 
presence of much higher concentrations of CCBE1 175 compared with those of full 
length CCBE1 (Fig. 15).  
 
 
 
 
 
 
 
 
Figure 15. A truncated form of CCBE1 lacking its C terminal collagen-like domain fails to drive 
VEGFC cleavage. (A) Full length CCBE1-V5 was detected as a 70-100 kDa smear that was expressed 
at lower levels than the 25 kDa CCBE1 175-V5. (B) VEGF VHD-FLAG was incubated with control 
conditioned medium, conditioned medium containing full length CCBE1-V5 and conditioned medium 
containing CCBE1 175-V5 for 24 hours prior to anti-FLAG immunoblot. NT, amino terminus; VHD, 
VEGF homology domain. 
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These studies reveal that the N-terminal domain of CCBE1 is not sufficient to drive 
proteolytic cleavage of VEGFC, and suggest that previous studies using this peptide are 
not likely to accurately reflect CCBE1 function [a conclusion supported by recent in vivo 
structure function analysis of CCBE1 (Roukens et al., 2015)]. Possible roles for the 
CCBE1 N-terminal domain in potentiating VEGFC proteolysis in vivo, e.g. localizing the 
protein or interacting with other regulatory factors, require further studies to determine.  
Another interesting question is to understand the functional structure of CCBE1 by 
analyzing CCBE1 post-translational modifications. A series of enzymatic studies 
revealed that chondroitinase is specific in removing chondroitin-sulfate post-translational 
modification in the C-terminal domain of CCBE1, resulting in a distinct band at 55 kDa 
rather than a smear as normally observed.  Treatment with PNGase F also removed the 
N-linked glycans from CCBE1 (Fig. 16). The result showed CCBE1 is a chondroitin 
sulfated and N-glycosylated secreted protein.   
 
 
 
 
 
 
 
Figure 16. Post-translational modification of CCBE1. CCBE1 is chondroitin sulfated and N-
glycosylated. HEK293T conditioned supernatant generated by transfection with CCBE1-V5 plasmid 
was treated with the indicated enzymes prior to western blot analysis. This assay was done by Dr. 
David Enis.  
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3.5 Activation of VEGFR3 by VEGFC requires N and C-terminal proteolysis 
and is driven by CCBE1 in vitro 
Previous studies of VEGFC processing have assessed its functional impact on VEGFC 
activity by measuring binding to VEGFR3 ectodomain and common signaling endpoints 
such as activation of ERK1/2 and AKT. These endpoints are not ideal because 
unprocessed VEGFC may bind but not activate the receptor, and ERK and AKT are 
promiscuous downstream signaling pathways that do not specifically measure VEGFR3 
signaling. In contrast, our biochemical experiment suggested that HEK293T conditioned 
medium is capable of promoting level of p-Akt and p-ERK without any introduction of 
VEGFC (data not shown). 
To better assess the functional significance of CCBE1 and VEGFC processing, we 
therefore measured the phosphorylation level of VEGFR3 receptors in primary lymphatic 
endothelial cells (LECs) using a phospho-VEGFR3 ELISA. The concept of this ELISA 
assay is that once active VEGFC binds to its receptor, a number of tyrosine residues 
including Tyr1068 on the C-tail domain of VEGFR3 are phosphorylated (mentioned in the 
introduction section).  These phosphorylated tyrosines can be detected by anti-phospho-
tyrosine-HRP antibody and quantified by colorimetric analysis to provide relatively 
accurate concentration of phosphorylated VEGFR3 receptors. Exposure of primary 
human LECs to VEGFC containing conditioned medium without added CCBE1 resulted 
in little or no increase in the level of phospho-VEGFR3 as ligand concentration was 
increased from 5 to 20 nM (as negative control). Exposure of LECs to VEGFC+CCBE1 
mix resulted in a dose-dependent increase in the level of phosphorylated VEGFR3 that 
fully reproduced the response to an engineered VEGFCΔNΔC protein (as positive control) 
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(Fig. 17). This suggested that the increase in VEGFC ligand activity conferred by CCBE1 
is likely to be due to CCBE1’s role in facilitating N-terminal proteolysis. Furthermore, 
phospho-VEGFR3 has become a great tool to investigate relationships between VEGFC 
structure and its activity.  
 
 
 
 
 
 
 
Figure 17. Phospho-VEGFR3 was measured by ELISA. The LECs were under exposure to 5-20 nM 
concentration of VEGFC that was incubated with conditioned medium from control HEK293T cells 
(HEK293T CM) or CCBE1-V5 (CCBE1) or following exposure to VEGFC ΔNΔC-Fc. N=3 for each 
concentration; error bars indicate SEM. 
 
To directly test this mechanism, and better characterize it at the molecular level, we 
isolated the single 19/21 kDa band of VEGFC VHD-FLAG generated by exposure to 
CCBE1 and performed N-terminal Edman sequencing to identify the site of proteolytic 
cleavage. The N-terminal sequence of this peptide was AHYNTEILK, indicating that 
CCBE1 drives cleavage of VEGFC following the FAA sequence ending at amino acid 
A111 (Fig. 18).  With this information, investigating the cleavage site by generating point 
mutations has become possible. 
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Figure 18. Schematic representation of the VEGFC cleavage site facilitated by CCBE1. 
 
Identification of the CCBE1- associated N-terminal cleavage site allowed us to next 
generate a VEGFC mutant that cannot be cleaved at that site to directly test whether N-
terminal proteolytic cleavage is required for VEGFC activity on LECs. Mutation of the 
FAA-AHY sequence in VEGFC VHD-FLAG to LTT-TFY (VEGFC LTTTF) resulted in 
a protein that was well expressed by HEK293T cells but was not N-terminally cleaved in 
the presence of CCBE1 (Fig. 19). 
 
 
 
 
 
 
Figure 19. The VEGFC FAAAH109-113LTTTF mutant is not N terminally cleaved in the presence of 
CCBE1. The five amino acids FAAAH were replaced by LTTTF using site-directed mutagenesis 
approach. The mutant was uncleavable at its N-terminus. NT, amino terminus; VHD, VEGF 
homology domain.  
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Phospho-VEGFR3 ELISA showed that VEGFC-LTTTF (VEGFC NT uncleavable) 
conferred no increase in phospho-VEGFR3 in primary LECs, with or without CCBE1 
exposure. In contrast, wild-type VEGFC exhibited marked increases in phospho-
VEGFR3 that were CCBE1-dependent (Fig. 20). These studies demonstrate that CCBE1-
driven proteolysis of VEGFC is required for the ligand to activate the VEGFR3 receptor, 
and that the effect of CCBE1 on VEGFC activity is mediated by N-terminal cleavage. 
  
 
 
 
 
 
 
 
Figure 20. The N terminally uncleavable VEGFC (NT uncleavable) is unable to activate VEGFR3. 
Phospho-VEGFR3 ELISA was performed as described using the indicated concentrations (5-20 nM) 
of wild-type and NT uncleavable VEGFC, with and without CCBE1. N=3 for each concentration; 
error bars indicate SEM.  
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Similar to VEGFC NT uncleavable mutant, the CT uncleavable (VEGFC RR226/227SS-
V5) induced no increase in phospho-VEGFR3 regardless of CCBE1 presence (Fig. 21). 
This result confirmed that VEGFC activation requires both NT and CT to be removed. 
The proteolytic activation of VEGFC, therefore, must be specifically regulated at both N- 
and C-termini of the growth factor. 
 
 
 
 
 
 
 
 
 
Figure 21. C terminal cleavage of VEGFC is required for activation of VEGFR3 independent of N 
terminal cleavage. LEC phospho-VEGFR3 was measured after exposure to wild-type VEGFC that is 
tagged in its VHD (“VEGFC-VHD-FLAG”) or VEGFC with an uncleavable C terminus (the 
RR226/227SS mutant) that is tagged at its carboxyl terminus (“VEGFC-CT-unclev V5”). N=3 for 
each concentration; error bars indicate SEM.  
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3.6 VEGFC activity towards VEGFR3 is reduced by increased length of the C 
terminus. 
In order to understand further the importance of C-terminal cleavage of VEGFC, we 
generated a series of engineered VEGFC constructs (VEGFCΔC-FLAG-V5, VEGFC-
VHD-FLAG-ΔC, and VEGFC-LTTTF-VHD-FLAG-ΔC) to investigate how external 
peptide sequences at the C-terminus might influence ligand activity (Fig. 22). The 
number of amino acids at the C-terminus of each construct was labeled. These constructs 
were expressed in HEK293T cells and conditioned media were collected for biochemical 
analysis. 
 
 
 
 
 
 
 
 
 
Figure 22. Schematic of VEGFC mutant proteins with varying uncleavable C terminal amino acids 
(with the number of amino acids C terminal of the VHD indicated). VEGFC-CT-unclev V5, the 
RR226/227SS mutant; VEGFCΔC-FLAG-V5, VEGFC without a C terminus in which serial FLAG and 
V5 epitopes have been fused in frame to the VHD; VEGFC-VHD -FLAG-ΔC, VEGFC without a C 
terminus to which a FLAG epitope has been fused in frame to the VHD; VEGFC (LTTTF)-VHD -
FLAG-ΔC, VEGFC with a mutation blocking ADAMTS3 cleavage of the N terminus that also lacks a 
C terminus and to which a FLAG epitope has been fused in frame to the VHD. NT, amino terminus; 
VHD, VEGF homology domain; CT, carboxyl terminus. 
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The phospho-VEGFR3 ELISA assay showed the level of phosphorylated VEGFR3 was 
reduced when external peptide was added after the CT cleavage site of VEGFC (Fig. 23). 
The 22 amino acids encoding Flag-V5 tags after the CT site of VEGFCΔC-FLAG-V5 
reduced phospho-VEFGR3, compared to VEGFC-VHD-FLAG-ΔC construct. In 
addition, the VEGFC (LTTTF)-VHD-FLAG-ΔC conferred no increase in phospho-
VEGFR3 in primary LECs, confirming the requirement of N-terminal cleavage for 
VEGFC activity. These findings demonstrated how tightly the NT and CT processing 
must be regulated to assure the correct activation for VEGFC. 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. The length of C-terminal peptide determines VEGFC affinity towards VEGFR3. (A) 
Expression of the VEGFC mutant proteins described in by HEK293T cells and their cleavage 
following incubation with ADAMTS3-containing conditioned medium. (B) The ability of the VEGFC 
mutants to activate VEGFR3 was measured using a phospho-VEGFR3 ELISA. N=3 for each 
concentration; error bars indicate SEM.  
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3.7 CCBE1 is required for VEGFC processing in vitro 
Most of our biochemical results indicated that CCBE1 facilitates VEGFC processing, 
thus the question to be address is whether lack of CCBE1 might inhibit VEGFC cleavage 
in vitro. Here, we utilized the “Clustered regularly interspaced short palindromic repeats 
(CRISPR)/ CRISPR-associated proteins (Cas) 9” (CRISPR/Cas 9) technique to create 
double strand breaks in the signal peptide sequence of CCBE1. Sequencing mRNA 
transcripts confirmed disruption in the signal peptide of all CCBE1 alleles, thus hindering 
the protein expression (data not shown). Endogenous expression of VEGFC in CCBE1-
deficient HEK293T does not undergo N-terminal processing within a 24-hour period, 
compared to HEK293T wild type (Fig. 24). Therefore, lack of CCBE1 inhibits VEGFC 
N-terminal cleavage in vitro.   
 
 
 
 
 
Figure 24. CCBE1 is required for VEGFC processing in vitro. The level of endogenous VEGFC 
processing was undetectable in the CCBE1-deficient cells within 24 hours of incubation, compared to 
HEK293T wild types. NT, amino terminus; VHD, VEGF homology domain. 
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3.8 Chapter discussion 
A novel accomplishment in this study was that we were able to engineer VEGFC 
construct into a robust biochemical tool to follow its proteolysis in vitro. Prior studies 
have used either S35 radiolabelling or a single VEGFC VHD antibody to follow VEGFC 
processing. The data have often been very hard to interpret (e.g. due to the requirement 
for VEGFR3 ectodomain pull-down to interpret the radiolabelling experiments) and have 
prevented direct detection of VEGFC proteolysis. Our introduction of VHD-tagged 
VEGFC greatly contributed to solve any uncertainty, which had been raised due to 
limitations of previous approaches like weak anti-VEGFC antibody or VEGFR3 pull-
down. In combination with protein overexpression in HEK293T cells, the FLAG epitope 
tag was able to provide clear and unambiguous detection of VEGFC ligand at different 
stages during its proteolysis; VHD (19-21 kDa), NT+VHD (35 kDa), and NT+VHD+CT 
(58-60 kDa). Phospho-VEGFR3 ELISA assay, as read-out for VEGFC activity, provided 
reliable and consistent evidence that VEGFC remains inactive until both NT and CT are 
precisely cleaved off. These results also suggested that VEGFC activity is mostly decided 
by it proteolytic processing that occurs even in absence of VEGFR3 receptor or LECs. 
For the first time, VEGFC has been shown to undergo proteolytic cleavages that are 
independent of VEGFR3.  
The biochemical data demonstrated a strong relationship between secreted CCBE1 and 
lymphangiogenic factor VEGFC in vitro. Prior to this point, CCBE1 has been in a long 
discussion whether its function involves in VEGFC proteolysis (Bos et al., 2011; Le 
Guen et al., 2014). Our assays not only confirmed the requirement of CCBE1 in VEGFC 
processing, but also displayed how CCBE1 regulated VEGFC activity by facilitating NT 
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cleavage. We also revealed N-terminal domain of CCBE1 (CCBE 175) is not sufficient to 
drive proteolytic cleavage of VEGFC that requires full-length chondroitin sulfated and N-
glycosylated CCBE1.    
Joukov et al. reported the inactive CT uncleavable mutant VEGFC (i.e. VEGFC 
RR226/227SS) and detected two cleavage sites at N-terminus of VEGFC, which are after 
either R102 or A111 amino acids in 1997. For almost 20 years, it has not been concluded 
which of the two sites is responsible for VEGFC activation. Nevertheless, with our 
FLAG tag, we were able to isolate the VEGFCΔNΔC protein, sequence, and determine the 
CCBE1-faciliated cleavage site is at FAA111êAHY. This novel finding also enabled us to 
generate the NT uncleavable mutant of VEGFC (i.e. VEGFC LTTTF), which completely 
inhibits VEGFC activity. This confirms the requirement of NT removal for VEGFC 
activation. Furthermore, one of our challenges at this stage was to identify which protease 
drives the NT cleavage. FAA is a specific recognition sequence for metalloproteinases, 
especially ADAMTS2 and ADAMTS3 (Colige et al., 2005), which intrigued our next 
investigation into ADAMTS3.    
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CHAPTER FOUR 
ADAMTS3 is an indispensible component of the VEGFC processing complex 
4.1 Rationale 
The finding of the precise location of the N-terminal cleavage site of VEGFC that is 
facilitated by CCBE1 revealed proteolysis at FAAêAHYN, a sequence resembling that at 
which collagen is processed by the ADAMTS2 and ADAMTS3 proteases (Colige et al., 
2005). This result is consistent with a previous report implicating ADAMTS3 in CCBE1-
mediated VEGFC processing by HEK293 cells (Jeltsch et al., 2014). It is, therefore, 
inevitable to investigate the role of ADAMTS3 in the context of VEGFC proteolysis. 
From the time of its identification, ADAMTS3 has not yet been studied intensively both 
in vitro and in vivo. In order to understand this protein, we utilize CRISPR/ Cas9 
technique to modify the signal peptide sequence of ADAMTS3, thus shutting the protein 
expression in HEK293T cells. This technique generated a novel biochemical tool that 
provides an ADAMTS3-free in vitro environment.  With this tool, we could investigate 
not only the functional activity, but also structural features of ADAMTS3 in vitro that 
ultimately provided supporting evidences for existence of the VEGFC processing 
complex. 
On the other hand, our preliminary data suggested the proteolytic regulation of VEGFC 
and its homolog VEGFD are potentially different. The biochemical comparison between 
the two lymphangiogenic factors is also discussed in this chapter, which strongly 
demonstrates evidence for distinct mechanisms of proteolytic activation between VEGFC 
and VEGFD. 
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4.2 EDTA blocks VEGFC processing 
The metalloproteinase ADAMTS3 is a cation-dependent protease, activity of which could 
be blocked by addition of EDTA. Addition of EDTA at 4 mM and 8 mM concentration to 
mixed media containing both VEGFC and CCBE1 blocked the N-terminal cleavage of 
VEGFC after 18 hours of incubation (Fig. 25). This finding was consistent with 
metalloprotease activity, which requires Zn2+ to switch on the active site from its 
precursor form.  However, this result could only illustrate VEGFC processing requires 
cations but it was not conclusive enough to state that ADAMTS3 is inactive. It is known 
that the EGF-like domains of CCBE1 are also predicted to bind calcium and the result 
might therefore reflect inactivation of CCBE1 function rather than inactivation of the 
candidate protease. We, therefore, investigated the effect of ADAMTS3 deficiency on 
VEGFC processing in the context of HEK293T cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Addition of EDTA reveals that CCBE1-dependent VEGFC proteolysis is cation 
dependent. VEGFC could only be processed in the presence of CCBE1; however, this cleavage is 
blocked at the concentrations of 4mM and 8mM EDTA that depletes free cations. NT, amino 
terminus; VHD, VEGF homology domain. 
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Figure 4.  ADAMTS3 is required for N terminal VEGFC proteolysis in 
HEK293T cell supernatant.  (A) Incubation with EDTA reveals that CCBE1-
dependent VEGFC proteolysis is cation dependent.  (B) The ADAMTS3 gene 
was disrupted in HEK293T cells using CRISPR/Cas9 to generate disabling 
mutations in the sequence encoding the ADAMTS3 signal peptide.  TSP, 
thrombospondin1 motif.  (C) Incubation of VEGFC VHD-FLAG and CCBE1-V5 
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4.3 Deletion of ADAMTS3 eliminates VEGFC processing in HEK293T cells 
To overcome the concern of unspecificity and more definitively test the requirement for 
ADAMTS3, we next used CRISPR-Cas9 technique (Perez-Pinera et al., 2013) to mutate 
the sequence in the ADAMTS3 gene that encodes the protease’s signal peptide in 
HEK293T cells (Fig. 26A). Analysis of HEK293T clonal populations generated after 
transfection with a plasmid-encoding guide RNAs targeting this sequence and Cas9 
revealed that HEK293T cells are triploid for the ADAMTS3 gene (consistent with prior 
cytogenetic studies Bylund et al., 2004). HEK293T clones with mutations predicted to 
disable 1, 2 or 3 ADAMTS3 alleles were identified. Analysis of VEGFC VHD-FLAG 
processing following expression of VEGFC and CCBE1 in ADAMTS3 mutant 
HEK293T cell clones revealed complete processing in cells with 3 copies, partial 
processing in cells with 1 or 2 copies, and a total loss of processing in cells with no wild 
type ADAMTS3 alleles (Fig. 26B). Thus progressive loss of ADAMTS3 alleles resulted 
in a dose-dependent reduction in CCBE1-driven VEGFC proteolysis. The ADAMTS3-
deficient cell line has become a great tool for investigating the function of ADAMTS3 
since it provides an ADAMTS3-free environment. This loss-of-function study suggested 
ADAMTS3 is required for VEGFC processing in vitro; therefore, the next study would 
be to examine whether ADAMTS3 directly mediates N-terminal cleavage of VEGFC. 
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Figure 26. ADAMTS3 is required for N terminal VEGFC proteolysis in HEK293T cells. (A) The 
ADAMTS3 gene was disrupted in HEK293T cells using CRISPR/Cas9 to generate disabling 
mutations in the sequence encoding the ADAMTS3 signal peptide. TSP, thrombospondin1 motif. (B) 
Incubation of VEGFC VHD-FLAG and CCBE1-V5 generated by expression in HEK293T cell clones 
with 3 (wt), 2 (4D5), 1 (4F9), or 0 (4C2) wild-type ADAMTS3 alleles revealed a dose-dependent loss 
of VEGFC proteolysis with loss of ADAMTS3. NT, amino terminus; VHD, VEGF homology domain. 
The ADAMTS3-deficient HEK293 cells were generated by Dr. David Enis and Jennifer Cohen.  
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4.4 ADAMTS3 exclusively mediates the CCBE1-dependent VEGFC proteolytic 
processing event in HEK293T cells 
CRISPR-Cas9 genome editing is highly efficient, but may also result in off-target 
mutations (according to Doudna and Charpentier, 2014). Thus, it is possible that clones 
exhibiting greater loss of ADAMTS3 alleles may also harbor larger numbers of off-target 
mutations, and that the loss of VEGFC processing may not be directly attributable to 
mutations in ADAMTS3. To further test the causal role for ADAMTS3 in CCBE1-
directed VEGFC processing in vitro, we next expressed ADAMTS3-V5 in a HEK293T 
cell clone that lacked all wild-type ADAMTS3 genes and did not support VEGFC 
processing (clone 4C2). Expression of ADAMTS3-V5 revealed 2 bands of 220 and 240 
kDa molecular weights in cell lysate and number of smaller bands in conditioned 
supernatant, consistent with ADAMTS3 proteolysis in the extracellular environment (Fig. 
27A). Expression of ADAMTS3-V5 rescued VEGFC processing in the ADAMTS3-
deficient HEK293T mutant cell line, and drove highly efficient VEGFC processing in the 
absence of added CCBE1 (Fig. 27B). These genetic studies demonstrate that CCBE1-
driven VEGFC proteolytic processing is mediated exclusively by ADAMTS3 in HEK293 
cells. 
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Figure 27. ADAMTS3 mediates the CCBE1-dependent VEGFC proteolytic processing event. (A) 
Expression of ADAMTS3-V5 in HEK293T cells revealed a 220/240 kDa doublet in cell lysate and a 
number of smaller bands in conditioned supernatant consistent with extracellular proteolysis. (B) 
Expression of ADAMTS3-V5 rescued proteolytic processing of VEGFC VHD-FLAG in ADAMTS3-/-
/- HEK293T cells. NT, amino terminus; VHD, VEGF homology domain. 
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4.5 The catalytic metalloproteinase domain of ADAMTS3 is essential for 
VEGFC processing 
Being one of the first research groups to successfully engineer ADAMTS3 construct for 
the purpose of in vitro studies, we utilized this novel tool to carry out structural studies on 
the proteinase of interest. We generated a series of ADAMTS3 truncated mutants by 
introducing a stop codon at the end of each sequential structural domain as 
ADAMTS3ΔCT, ADAMTS3Δ3TSP, ADAMTS3ΔSpacer, ADAMTS3ΔCys-rich, and 
ADAMTS3Δ4TSP respectively. A V5 tag was added at the C-terminus of each construct to 
allow detecting protein expression and molecular weight. The expression of these 
constructs showed discrete change in molecular weight according to their designs (Fig. 
28). 
 
 
 
 
 
 
 
 
Figure 28. Generation of a series of ADAMTS3 truncation mutations; namely ADAMTS3ΔCT, 
ADAMTS3Δ3TSP (left), ADAMTS3ΔSpacer, ADAMTS3ΔCys-rich, and ADAMTS3Δ4TSP (right). All 
constructs were secreted and harvested in the ADAMTS3-deficient HEK293T conditioned media. 
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As these truncation mutants were successfully generated, we examined their activity in 
cleaving VEGFC N-terminus compared to ADAMTS3 full-length control. The 
biochemical results showed that all of these constructs were able to mediate VEGFC 
proteolysis (Fig. 29). It is interesting because the C-terminal domains of ADAMTS3 have 
been reported for substrate specificity in the context of pro-collagen maturation 
(Fernandes et al., 2001); here our data demonstrated that those domains are not crucial 
for cleaving VEGFC in vitro.  
 
 
Figure 29. ADAMTS3 truncation mutants were able to mediate VEGFC processing in vitro.  
Engineered ADAMTS3 constructs [ADAMTS3ΔCT and ADAMTS3Δ3TSP (left panel); 
ADAMTS3ΔSpacer, ADAMTS3ΔCys-rich, and ADAMTS3Δ4TSP (right panel)] were mixed with VEGFC-
VHD-FLAG for 18 hours at 37oC. All experimental steps were performed in the ADAMTS3-deficient 
HEK293T conditioned media. NT, amino terminus; VHD, VEGF homology domain. 
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The biochemical data intrigued our study with the fact that even most of the protein was 
removed; truncated ADAMTS3 constructs (as small as ADAMTS3Δ4TSP ~ 70kDa) were 
still able to perform VEGFC processing. This strongly suggests ADAMTS3 
metalloproteinase domain to play an indispensable role in cleaving VEGFC. In order to 
test this idea, we continued to remove the disintegrin-like domain, which has been 
discussed to be part of ADAMTS3 catalytic domain (Kelwick et al., 2015).  Interestingly, 
the mutant ADAMTS3ΔDisintegrin (~35kDa) could not process VEGFC-VHD-flag in mixed 
conditioned media, compared to full-length ADAMTS3 (Fig. 30). This result confirmed 
the importance of N-terminal ADAMTS3 catalytic domain to VEGFC proteolysis, rather 
than the C-terminal domains that might only be crucial for pro-collagen maturation 
(Colige et al., 2002). 
 
 
 
 
 
 
 
Figure 30.  ADAMTS3ΔDisintegrin mutant was unable to process VEGFC. The truncated construct 
ADAMTS3ΔDisintegrin could not cleave the NT (lane 3) that demonstrated lack of the disintegrin-like 
domain might deactivate the proteinase. All experimental steps were performed in the ADAMTS3-
deficient HEK293T conditioned media. NT, amino terminus; VHD, VEGF homology domain. 
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4.6 VEGFC, ADAMTS3, and CCBE1 interact in a single molecular complex – 
the VEGFC processing complex 
The biochemical studies suggested that VEGFC is cleaved by ADAMTS3 in a manner 
that is tightly regulated by CCBE1.  To better understand the molecular interactions that 
govern this regulatory mechanism, we next took advantage of epitope-tagged proteins to 
examine the physical association of these proteins by co-immunoprecipitation.  
Consistent with previously reported studies (Jeltsch et al., 2014), VEGFC-VHD-FLAG 
and CCBE1-V5 could not be co-precipitated from conditioned supernatant containing 
both proteins (Fig. 31), indicating that VEGFC and CCBE1 do not directly interact.   
 
 
 
 
 
 
 
Figure 31. VEGFC does not directly bind CCBE1. VEGFC VHD-FLAG and CCBE1-V5 conditioned 
media were mixed prior to immunoprecipitation with anti-V5 antibodies and immunoblot analysis 
with anti-FLAG antibodies. Precipitated CCBE1-V5 is shown below. 
 
In contrast, immunoprecipitation of CCBE1 from conditioned supernatant containing 
ADAMTS3-HA and CCBE1-V5 resulted in efficient co-precipitation of ADAMTS3 (Fig. 
32), indicating that ADAMTS3 and CCBE1 biochemically associate in a robust manner.  
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We also investigated binding of ADAMTS3 towards other CCBE1 mutant constructs like 
CCBE1 175 and CCBE1 D170E. ADAMTS3-HA could not be co-precipitated with 
CCBE1 175-V5, consistent with our previous functional studies demonstrating an 
inability of this truncated CCBE1 protein to drive VEGFC N-terminal cleavage.  
Consistent with this result, CCBE1 D170E-V5, a CCBE1 protein with a mutation in the 
N-terminal domain that causes loss of lymphatic growth in zebrafish embryos in vivo 
(Hogan et al., 2009), retained strong interaction with ADAMTS3.  Unexpectedly, a small 
amount of ADAMTS3-HA could be co-precipitated with VEGFC-V5, suggesting that 
VEGFC may pull down some ADAMTS3 in a manner that is dependent upon 
endogenous HEK293T CCBE1 (Fig. 32).   
 
 
 
 
 
 
 
 
 
Figure 32. ADAMTS3 co-precipitates with full length but not N-terminal CCBE1. The indicated 
conditioned media were mixed and CCBE1-V5 immunoprecipitated. Co-precipitated ADAMTS3-HA 
is shown above and precipitated CCBE1-V5 proteins are shown below. This assay was done with the 
help of Mei Chen.  
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To test the possibility for the existence of a VEGFC-ADAMTS3-CCBE1 complex, we 
next expressed VEGFC-V5, ADAMTS3-HA, and untagged CCBE1; then repeated the 
VEGFC co-immunoprecipitation experiments.  In the presence of added CCBE1, 
VEGFC-V5 was able to efficiently pull down ADAMTS3-HA, which was not observed 
in the control lane (Fig. 33). This finding is consistent with an idea that CCBE1 plays as a 
co-factor to enhance the enzyme (ADAMTS3) – substrate (VEGFC) interaction.     
 
 
 
 
 
 
 
Figure 33. VEGFC co-precipitates with ADAMTS3 in a CCBE1-dependent manner.  Conditioned 
media containing ADAMTS3-HA and VEGFC-V5 were mixed alone and with media containing 
untagged CCBE1 prior to anti-V5 immunoprecipitation. Addition of CCBE1 enabled VEGFC to pull 
down ADAMTS3 (right lane) compared to control (left lane). 
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To further explore the nature of the VEGFC-ADAMTS3-CCBE1 complex, we repeated 
this experiment at 4oC, a temperature at which ADAMTS3 activity is expected to be 
reduced, at 37oC, a temperature at which ADAMTS3 activity is expected to be high, and 
in the presence of EDTA, a known inhibitor of ADAMTS(s) proteolytic activity.  As 
expected, lack of CCBE1 yielded low VEGFC-ADAMTS3 interaction regardless of 
physical conditions. In the presence of CCBE1, ADAMTS3 was efficiently co-
precipitated with VEGFC at 4oC and in the presence of EDTA, but not at 37oC (Fig. 34). 
At 37oC, ADAMTS3 protease activity was expected to resolve the VEGFC-ADAMTS3-
CCBE1 complex by cleaving off NT from VEGFC.   These findings support a molecular 
model in which ADAMTS3 binds VEGFC in a CCBE1-dependent manner to form a 
proteolytic complex that is required for ligand activation. 
 
 
 
 
 
 
 
 
Figure 34. ADAMTS3-CCBE1 release of VEGFC requires ADAMTS3 enzymatic activity. VEGFC 
co-precipitation with ADAMTS3 was performed in the presence of untagged CCBE1 at 4oC, 37oC 
and in the presence of EDTA to inhibit metalloprotease activity. Note that VEGFC was retained at 
4oC and in the presence of EDTA, conditions that block ADAMTS3 enzymatic activity. This assay 
was done with the help of Mei Chen.  
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4.7 VEGFD processing is independent of both CCBE1 and ADAMTS3 
VEGFC and VEGFD are homologous proteins that activate VEGFR3, and VEGFD 
contains N and C terminal domains that are proteolytically processed in a manner 
analogous to those in VEGFC (Stacker et al., 1999). As for VEGFC, a number of 
different proteases have been implicated in the proteolytic processing of VEGFD 
(McColl et al., 2003). Zebrafish genetic studies have recently suggested that VEGFD 
function may be regulated by CCBE1 (Astin et al., 2014), but biochemical studies have 
not revealed an effect of CCBE1 or ADAMTS3 on VEGFD processing (Jeltsch et al., 
2014). To directly compare the processing of these two lymphangiogenic growth factors, 
we generated VEGFD VHD-FLAG in a manner analogous to that used to generate 
VEGFC VHD-FLAG. VEGFD VHD-FLAG secreted from HEK293T cells appeared as 3 
distinct 52, 33 and 19 kDa bands, consistent with proteins containing NT+VHD+CT, 
VHD+CT and VHD domains respectively (Fig. 35). Moreover, addition of EDTA at the 
concentrations of 4mM and 8mM did not change the expression pattern of VEGFD 
showing that VEGFD could be processed by a non-metalloproteinase. This in vitro 
observation is contrast to how EDTA affected VEGFC processing (Section 4.2) 
suggesting VEGFC and VEGFD are proteolytically regulated in two different processing 
pathways. 
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Figure 35. VEGFD expression in HEK293T cells. Addition of EDTA had no effect on VEGFD 
processing. NT, amino terminus; VHD, VEGF homology domain; CT, carboxyl terminus. The 
VEGFD VHD-FLAG construct was designed by Dr. David Enis.  
 
As the proteolytic processing of VEGFD is distinct from that of VEGFC, we wonder 
what the cleavage site at the N-terminus of VEGFD is. To address this question, N-
terminal Edman sequencing of the 19 kDa, fully processed VEGFD VHD-FLAG protein 
expressed by HEK293T cells revealed cleavage after R88 (Fig. 36). This is surely 
interesting because cleavage after an arginine residue strongly indicates a serine protease 
substrate. This result confirmed the cleavage site reported by McColl et al. (2007). 
 
 
 
 
Figure 36. N-terminal sequencing of the 19-kDa band observed in VEGFD VHD-FLAG- expressing 
medium revealed cleavage after R88. NT, amino terminus; VHD, VEGF homology domain; CT, 
carboxyl terminus.  
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In contrast to VEGFC, exposure of VEGFD VHD-FLAG to either CCBE1-V5 or 
ADAMTS3-V5 did not increase the fraction of low molecular weight, fully processed 
protein. Conversely, expression of VEGFD VHD-FLAG in ADAMTS3- deficient 
HEK293T cells did not reduce the fraction of low molecular weight, fully processed 
protein (Fig. 37). These in vitro results were consistent with previous studies (McColl et 
al., 2007), and demonstrate that despite their structural and sequence homology VEGFC 
and VEGFD are processed by distinct enzymatic processes in HEK293T cell conditioned 
medium.	   
 
 
 
 
 
 
Figure 37. VEGFD VHD-FLAG proteolysis is independent of ADAMT3 and CCBE1. VEGFD 
processing was not increased by incubation with conditioned medium containing CCBE1 (lane 2) or 
ADAMTS3 (lane 3) or lack of ADAMTS3 (lane 4).  NT, amino terminus; VHD, VEGF homology 
domain; CT, carboxyl terminus. 
 
Here, we demonstrated with supporting evidence that VEGFD processing is independent 
of ADAMTS3/ CCBE1, thus suggesting a distinct mechanism for its proteolytic 
activation from that of VEGFC.  
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4.8 Plasmin greatly enhances VEGFD processing but not VEGFC processing in 
HEK293T cells 
VEGFD has been reported to be a substrate of plasmin, a serine protease abundantly 
found at injury/ wound sites (McColl et al., 2003), therefore it is necessary to confirm 
this result with our internal VHD-FLAG VEGFC and VEGFD constructs. Plasmin, 
incubated with VEGFD-VHD-FLAG, revealed complete processing at 10 units (U)/mL 
concentration (equivalent to 10 µmole of VEGFD per minute per mL) within 2 hours, 
whereas the enzyme availability might not be sufficient to digest VEGFD at lower 
concentration of plasmin (0.1 U/mL). This result indicated VEGFD proteolysis is dose-
dependent of plasmin (Fig. 38). 
 
 
 
 
 
 
 
Figure 38. Plasmin enhances VEGFD processing. VEGFD-VHD-FLAG was incubated with plasmin 
at different concentrations (10 U/mL, 0.1 U/mL, and 0.001 U/mL respectively) for 2 hours and 
samples were taken at regular intervals (30 min, 1 hour, and 2 hours). Complete proteolysis of 
VEGFD was observed at 10 U/mL plasmin. NT, amino terminus; VHD, VEGF homology domain; 
CT, carboxyl terminus. 
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On the other hand, plasmin at different concentrations was incubated with VEGFC-VHD-
FLAG, revealed incomplete digestion of VEGFC, and indicated potential degradation of 
substrate (at 10 U/mL of plasmin) within 2 hours (Fig. 39). The band representing VHD 
structure (21 KDa) did not show up as product of VEGFC proteolysis in presence of 
plasmin. ADAMTS3 was used as positive control for this assay. This result showed 
plasmin does not activate VEGFC through proteolysis. 
 
 
 
 
 
 
 
Figure 39. Plasmin unspecifically digests VEGFC. VEGFC-VHD-FLAG was incubated with plasmin 
at different concentrations (10 U/mL, 0.1 U/mL, and 0.001 U/mL respectively) for 2 hours and 
samples were taken at regular intervals (30 min, 1 hour, and 2 hours). ADAMTS3 was used as 
positive control. NT, amino terminus; VHD, VEGF homology domain; CT, carboxyl terminus. 
 
These findings not only confirmed in vitro observations reported by other research 
groups, but also indicated plasmin could be a regulator for VEGFD activity in vivo. The 
latter idea was indeed followed up with in vivo studies in inflammation and wound 
healing models, where the presence of plasmin is abundant.  
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4.9 Chapter discussion 
Prior to the start of this study, ADAMTS3 has only been known as a procollagen N-
propeptidase, which facilitates collagen maturation (Fernandes et al., 2001; Colige et al., 
2005). Here, the biochemical assays demonstrated a novel finding by revealing 
ADAMTS3 as a direct mediator of VEGFC N-terminal proteolysis. Both loss-of-function 
and rescue experiments indicated ADAMTS3 is the sole protease that cleaves VEGFC N-
terminus. Our finding, therefore, was consistent with that was suggested by Jeltsch et al. 
(2014), but also extended further to generate an ADAMTS3-free in vitro environment. 
HEK293T cells are able to express endogenous ADAMTS3 and CCBE1, which can 
process overexpressed VEGFC if enough time is given. This problem normally leads to 
false positive read-outs or lack of negative control in VEGFC proteolysis or phospho-
VEGFR3 ELISA assays. The ADAMTS3-deficient HEK293T cell line enabled our study 
to overcome those experimental limitations, as well as to conduct ADAMTS3 structural 
study. For many years, ADAMTS3 has been solely considered as a procollagen activator, 
and its enzymatic specificity was reported to be dependent on C-terminal domains 
(Fernandes et al., 2001). Our series of truncated ADAMTS3 mutants showed that most of 
the C-terminal domains are dispensable in the context of VEGFC proteolysis, and the N-
terminal catalytic domain is responsible for cleaving VEGFC.  Interestingly, as soon as 
one or more of C-terminal domains is removed, truncated proteins became more 
vulnerable to protein degradation, resulting in additional lower bands on the blot. This 
observation suggested the C-terminus domains are important for ADAMTS3 structural 
integrity.  
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A key molecular finding in this study is that VEGFC, ADAMTS3, and CCBE1 form a 
trimolecular complex that is required to proteolytically activate VEGFC, and that this 
activation mechanism can take place in the extracellular environment in a manner that 
does not require the LEC or the VEGFR3 receptor.  Previous studies have revealed a role 
for CCBE1 in VEGFC proteolysis (Le Guen et al., 2014; Roukens et al., 2015) and 
suggested that ADAMTS3 cleaves VEGFC (Jeltsch et al., 2014), but a clear picture of 
how these secreted proteins interact and how their interaction regulates lymphatic 
vascular growth has not emerged. Here, our studies demonstrated that ADAMTS3 
strongly associates with CCBE1, whereas both CCBE1 and ADAMTS3 individually have 
low binding affinity towards VEGFC. Only when all three components are present, the 
temperature sensitive VEGFC/ ADAMTS3/ CCBE1 complex is formed. Our model of 
VEGFC processing was proposed to report our understanding on how VEGFC undergoes 
N-terminal proteolysis (Fig. 40). Secreted protease ADAMTS3 does not bind readily to 
VEGFC, thus the proteolysis is regulated via the formation of VEGFC processing 
complex. When secreted CCBE1 interacts with ADAMTS3, it potentially causes a 
conformational change in the structure of ADAMTS3, allowing the protease to associate 
with VEGFC spatially and temporally. The complex remains stable until required 
conditions are met, then ADAMTS3 executes its enzymatic activity to release NT from 
VHD, which triggers VEGFC/ VEGFR3 signaling cascade. Since it was shown that 
VEGFC processing complex could form in absence of LECs or VEGFR3 receptor, it is 
possible that the localizing factor of this complex might lie in the N-terminal domains of 
CCBE1 (i.e. CCBE1 175), which is not responsible for facilitating VEGFC proteolysis. 
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This localization event could be mediated through binding of CCBE1 to extracellular 
matrix (ECM) to bring the complex spatially to cell surfaces during lymphatic growth.  
It has generally been thought that VEGFC and VEGFD are functionally redundant 
VEGFR3 ligands since gain of function studies revealed that VEGFC and VEGFD have 
equally powerful lymphangiogenic effects in vivo (Rissanen et al., 2003, Anisimov et al., 
2009), but genetic loss of function studies have only demonstrated a critical role for 
VEGFC during lymphatic development but not VEGFD (Karkkainen et al., 2004; Koch 
et al., 2009). Our Edman sequencing study and that of Marc Achen’s group concur in the 
identification of the VEGFD site of N terminal cleavage following expression in HEK 
cells ex vivo. Both labs identify primary cleavage immediately following the R88 in the R-
FAA sequence, which is consistent with VEGFD cleavage by a serine protease. The 
finding that VEGFD proteolysis takes place independently of ADAMTS3 and CCBE1 in 
vitro demonstrates a remarkable difference in the proteolysis regulation of the two 
lymphangiogenic factors that suggests new insight into their distinct in vivo roles. Key 
support for this division of lymphangiogenic labor is that ADAMTS3 is exclusively 
required for VEGFC proteolysis but not VEGFD.  In contrast, our studies confirmed 
plasmin, a fibrinolytic serine protease that is activated at sites of tissue injury and 
inflammation (Romer et al., 1996), as capable of cleaving VEGFD (McColl et al., 2007). 
Further in vivo studies that more precisely define the distinct roles of VEGFC versus 
VEGFD in established models of wound healing/ inflammatory lymphangiogenesis 
would help test this partitioned model of VEGFC and VEGFD lymphangiogenic 
function. 
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Figure 40. Molecular mechanisms of VEGFC and VEGFD activation. VEGFC is activated by a 
VEGFC-ADAMTS3-CCBE1 complex formation (left). CCBE1 binding to ADAMTS3 via the CCBE1 
C terminus (left) is predicted to confer a conformational change that permits the enzyme to associate 
with and cleave VEGFC (middle). N terminal cleavage of VEGFC releases the VHD that is able to 
activate VEGFR3 on the lymphatic endothelial cell (LEC). The CCBE1 N terminus may bind 
extracellular matrix (ECM) to localize the complex spatially during lymphatic growth. In contrast, 
VEGFD is activated independently of ADAMTS3 and CCBE1, most likely through a serine protease 
generated at sites of inflammation (right). The disulfide bond represents the fifth immunoglobulin-like 
(Ig-like) domain of VEGFR3, which is proteolytically processed. 
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CHAPTER FIVE  
Investigation of the VEGFC processing complex in vivo 
5.1 Rationale 
Our biochemical studies have demonstrated strong evidence for the existence of VEGFC 
processing complex in vitro, in which CCBE1 and ADAMTS3 are required as 
indispensable components of the complex. Our next goal was to examine whether this 
hypothesis would hold its validity in vivo. Published studies have demonstrated that 
CCBE1 can enhance the lymphatic endothelial cell (LEC) response to VEGFC in mice 
(Jeltsch et al., 2014) and in fish (Le Guen et al., 2014), but direct assessment of the role 
of CCBE1 in VEGFC-mediated LEC responses in vivo is not possible in the developing 
mouse or fish because loss of CCBE1 results in a complete absence of lymphatic vessels 
(Hogan et al., 2009; Bos et al., 2011).  Using the conditional Ccbe1-deficient mouse 
model developed in the lab (Zou et al., 2013), we were able to confirm the role of 
CCBE1 in postnatal lymphatic growth mediated by VEGFC but not VEGFD. 
Furthermore, the Adamts3-deficient mice (from KOMP) displayed lack of embryonic 
lymphatics that also demonstrated the requirement of this specific metalloproteinase in 
lymphangiogenesis in vivo, despite of being highly homologous to ADAMTS14 and 
ADAMTS2. Therefore, our in vivo evidences, in line with the in vitro findings provided 
strong insight and understanding into the mechanism in which VEGFC is processed by 
ADAMTS3 and CCBE1.  
This chapter was greatly contributed by the in vivo work from Dr. David Enis, a former 
postdoctoral fellow in the Kahn lab.  
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5.2 CCBE1 is dispensable for the maintenance of mature lymphatic vessels  
To directly address the role of CCBE1 in postnatal lymphangiogenesis, we deleted 
CCBE1 in conditional Ub-CreERT2;Ccbe1fl/- animals at timely manner. Neonatal 
induction of Ccbe1 deficiency at birth showed lack of lymphatic (LYVE1+) vessels in the 
ear and the skin, sites of postnatal lymphangiogenesis, by age 4 weeks (Fig. 41). CCBE1, 
as during embryogenesis, is required for new lymphatic vessel growth after birth.  
 
 
Figure 41. CCBE1 is required for postnatal lymphatic vessel growth. Tamoxifen was administered to 
Ub-CreERT2;Ccbe1fl/- (“neonatal CCBE1 KO”) and Ccbe1fl/- littermate (“control”) animals 
immediately after birth and analyzed at age 4 weeks. (A-D) The lymphatic network of the ear assessed 
by anti-LYVE1 whole-mount staining. Images shown are representative of 4 separate experiments.  
(E-H)  Neonatal CCBE1 KO animals exhibit reduced lymphatic density in the skin.  Imaging of dorsal 
skin lymphatics in Prox1-GFP animals (E & F) and LYVE 1 immunostaining of skin sections (G & 
H).  Arrows point to cutaneous lymphatic vessels. Images shown are representative of 3 separate 
experiments. Scale bars indicate 50 microns. The assay was done by Dr. David Enis.  
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On the other hand, no abnormality was observed when CCBE1 was deleted after growth 
and maturation of the lymphatic network was complete. Deletion of Ccbe1 in mature 12 
week-old Ub-CreERT2;Ccbe1fl/- animals (“adult CCBE1 KO” animals) using long-term, 
oral tamoxifen administration exhibited normal lymphatic vessel density and wild-type 
levels of LEC VEGFR3 (Fig 42). Thus, CCBE1 is required for lymphatic development 
and growth, but not for the maintenance of mature lymphatic vessels.  
 
 
Figure 42. CCBE1 is dispensable for the maintenance of mature lymphatic vessels. Tamoxifen was 
administered to Ub-CreERT2;Ccbe1fl/- animals (“adult CCBE1 KO”) and Ccbe1fl/- control littermates 
that also carried the Prox1-GFP allele starting at age 12 weeks. (A-D) The cutaneous lymphatics 
assessed by fluorescence microscopy of the ear. Images shown are representative of 4 separate 
experiments. (E-H) LECs in adult CCBE1 KO animals express normal levels of the receptor 
VEGFR3. Arrows point to cutaneous lymphatic vessels. Images shown are representative of 4 separate 
experiments. Scale bars indicate 50 microns. The assay was done by Dr. David Enis. 
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5.3 CCBE1 is required for VEGFC to stimulate lymphatic endothelial cell 
proliferation in vivo 
To test whether CCBE1 specifically regulates VEGFC responses in vivo, we injected full-
length VEGFC (VEGFC-FL)-expressing adenoviral vectors into the skin of adult CCBE1 
KO and littermate control animals, and harvested after 72 hours.  The precise site of 
VEGFC expression was marked by red fluorescence generated from a small amount of 
co-injected adeno-mCherry (Fig. 43). This technique was extremely helpful for localizing 
the injection site, as it could not be identified without m-Cherry fluorescence.  
 
 
 
Figure 43. Detection of cutaneous adenoviral expression using adeno-mCherry. Adeno-mCherry was 
added to adeno-VEGFC-FL at the time of injection and the site of expression was identified using 
fluorescent microscopy prior to tissue harvest for assessment of lymphatic proliferation and cell 
number. Magnification of images shown is 10X. The assay was done by Dr. David Enis. 
 
 
 
 
Ad-mCherry injected dorsal skin
Visible light Fluorescence Merge
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LEC proliferation was measured by cell number, and mitotic index calculated by 
immunostaining for BrdU that was injected 12 hours prior to sacrifice (Fig. 44). In 
control animals, adenoviral expression of VEGFC-FL stimulated strong LEC 
proliferation that was manifest by both the large fraction of LEC nuclei that were BrdU+ 
(approx. 35-40%) and by an increase in LEC cell number.  In contrast, adenoviral 
VEGFC-FL failed to stimulate any increase in BrdU uptake or LEC number in adult 
CCBE1 KO animals.   
 
 
 
 
 
 
Figure 44. VEGFC is not lymphangiogenic in adult Ccbe1-deficient animals. (A) Adenovirus 
expressing full length VEGFC (Ad-VEGFC-FL) was injected into the skin of Ub-CreERT2;Ccbe1fl/- 
animals in which Ccbe1 had been deleted by tamoxifen administration. Lymphatic vessels were 
analyzed 72 hours after adenovirus injection. Arrows indicate BrdU+ LEC nuclei. (B) The percentage 
of LEC nuclei that were BrdU+ (“mitotic index”) in the skin of adult CCBE1 KO and control animals 
following exposure to adenovirus expressing full length VEGFC is shown.  N=5 in each group; ** 
indicates P<0.001.  (C) LEC proliferation in the skin of adult CCBE1 KO and control animals 
following exposure to adenovirus expressing full length VEGFC was calculated by counting LEC 
nuclei per high power field.  N=5 in each group; * indicates P<0.01. Scale bars indicate 50 microns. 
The assay was done by Dr. David Enis. 
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To further test the role of CCBE1 in VEGFC-mediated responses in vivo, we attempted to 
rescue VEGFC-FL responses in adult CCBE1 KO mice by expression of CCBE1-V5.  
Injection of adeno-associated virus expressing CCBE1-V5 into the skin of adult CCBE1 
KO animals 4 weeks prior to the administration of VEGFC adenovirus successfully 
restored VEGFC-FL-induced LEC proliferation in adult CCBE1 KO animals (Fig. 45), 
confirming that loss of VEGFC responses is due specifically to the lack of CCBE1 and 
that CCBE1-V5 is biologically active in vivo. These studies demonstrate that CCBE1 is 
required for lymphatic endothelial responses to VEGFC in vivo, even when an intact 
lymphatic network is presented with very high levels of VEGFC ligand. 
 
 
 
 
 
 
 
 
Figure 45.  CCBE1-V5 rescues lymphangiogenesis in adult CCBE1 KO animals. Pre-treatment of 
adult CCBE1 KO skin with adeno-associated virus expressing CCBE1-V5 (AAV9-CCBE1-V5) 
restores the proliferative response of LECs to Ad-VEGFC-FL in adult CCBE1 KO animals. The 
BrdU+ cells in the adult CCBE1 KO skin that is exposed to only Ad-VEGFC-FL (lower right panel) 
are in the hair follicle. The data shown are representative of 5 separate experiments. Scale bars 
indicate 50 microns. The assay was done by Dr. David Enis. 
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5.4 The fully processed VEGFCΔNΔC bypasses CCBE1 requirement in vivo  
To this point, CCBE1 has been implicated in the proteolytic processing of VEGFC 
(Jeltsch et al., 2014), and transgenic expression of fully processed VEGFC (VEGFCΔNΔC) 
found to rescue lymphatic growth in ccbe1-deleted zebrafish embryos (Le Guen et al., 
2014). Our goal was to investigate the effects on lymphatic responses of full-length 
VEGFC compared to VEGFCΔNΔC in vivo. Injection of AAV9-VEGFC-FL that expresses 
full length VEGFC stimulated a modest lymphangiogenic response in the tibialis muscle 
(detected as discrete foci of lymphatic vessels) that was not observed in adult CCBE1 KO 
animals (Fig. 46). This result, again, confirmed that CCBE1 is required for VEGFC 
function both in vitro and in vivo.  
 
 
 
 
 
 
 
 
 
Figure 46.  CCBE1 is required for VEGFC-mediated lymphangiogenesis in tibialis muscle. Adeno-
associated virus (AAV9) expressing full length VEGFC (VEGFC-FL) was injected into the tibialis 
muscle of adult CCBE1 KO or control animals. Lymphatic growth was detected using LYVE1 and 
PROX1 immunostaining. Scale bars indicate 50 microns. The assay was done by Dr. David Enis. 
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To more directly assess the ability of VEGFCΔNΔC to drive lymphatic growth in Ccbe1-
deficient animals, we next expressed VEGFCΔNΔC in adult CCBE1 KO mice. AAV9-
VEGFCΔNΔC injection stimulated a highly robust growth of LYVE1+; PROX1+ lymphatic 
endothelium surrounding the muscle fiber sheaths in both control and CCBE1 KO 
animals (Fig. 47). This means VEGFCΔNΔC can promote lymphatic growth in Ccbe1- 
deficient animals, which strongly demonstrates the fully processed ligand VEGFCΔNΔC 
could bypass the requirement of CCBE1 in vivo and further implicate the role of CCBE1 
in the proteolytic processing of VEGFC in vivo.  
 
 
 
 
 
 
 
 
 
Figure 47.  The fully processed ligand VEGFCΔNΔC bypasses the requirement of CCBE1 in vivo. 
Adeno-associated virus (AAV9) expressing the core domain of VEGFC released by proteolysis of the 
N and C termini (VEGFCΔNΔC) was injected into the tibialis muscle of adult CCBE1 KO or control 
animals. Lymphatic growth was detected using LYVE1 and PROX1 immunostaining. Note that 
lymphatic growth stimulated by VEGFCΔNΔC tightly encircles muscle fibers and lacks the typical 
branched vascular appearance. Scale bars indicate 50 microns. The assay was done by Dr. David Enis. 
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5.5 VEGFD-mediated lymphangiogenesis is independent of ADAMTS3/ CCBE1 
in vivo 
Since VEGFD proteolysis is independent of ADAMTS3/ CCBE1 in vitro, we next 
expressed full length VEGFD in wild type and adult CCBE1 KO mouse muscle using 
adeno-associated virus to test whether VEGFC and VEGFD are activated through distinct 
mechanisms in vivo. In contrast to VEGFC, AAV9-VEGFD drove lymphatic vessel 
growth in both wild type and adult CCBE1 KO animals (Fig. 48). This means loss of 
CCBE1 did not hinder VEGFD-mediated lymphangiogenesis in vivo. Consistent with our 
in vitro results, these findings demonstrate that despite their strong amino acid and 
structural homology, VEGFC and VEGFD are processed by distinct proteases and are 
regulated independently. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48. VEGFD is lymphangiogenic in Ccbe1-deficient animals. Adeno-associated virus (AAV) 
expressing full length VEGFD (VEGFD-FL, left) was injected into the tibialis muscle of adult CCBE1 
KO or control animals. Lymphatic growth was detected using LYVE1 immunostaining and compared 
with mock-injected animals. The data shown are representative of 3 separate experiments. Scale bars 
indicate 50 microns. The assay was done by Dr. David Enis. 
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5.6 ADAMTS3 is required for lymphatic development in vivo 
Our in vitro studies revealed that ADAMTS3 plays a central and even necessary role in 
the proteolytic activation of VEGFC in HEK293T cell conditioned medium ex vivo.  
However, ADAMTS3 is highly homologous to ADAMTS14 and ADAMTS2, proteases 
that can also cleave procollagen and are also expressed in the developing mouse embryo 
(Bolz et al., 2001; Le Goff et al., 2006).  Thus, the ex vivo requirement for ADAMTS3 
may merely reflect a lack of expression of related proteases by HEK293T cells and not 
accurately predict its in vivo lymphangiogenic role.  To define the role of ADAMTS3 in 
vivo, we next studied lymphatic development in Adamts3-deficient mouse embryos that 
was generated by KOMP.  A null Adamts3 allele (Adamts3-) was induced by deletion of 
exon 3 in the Adamts3 gene, an event that removes the propeptidase domain and inserts 
multiple STOP codons immediately downstream of exon 2, resulting in an Adamts3 
mRNA predicted to encode a truncated protein lacking the catalytic domain (Fig. 49).   
 
 
 
 
 
 
 
Figure 49. Generation of Adamts3-/- mice using gene-trapped targeting. Gene targeting strategy for 
replacement of Adamts3 exon 3, flanked by 2 loxP sites, with an IRES-LacZ expression cassette is 
shown. All components were labeled accordingly. Figure was adapted from Sanger Institute technical 
data sheet.   
2
2
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Once the Adamts3- allele got into germ line, it provided heterozygous Adamts3+/- animals 
that were then intercrossed to generate Adamts3-/- embryos and littermate controls.  In 
E14.5 mouse embryos, the loss of ADAMTS3 resulted in severe cutaneous edema (Fig. 
50), a phenotype consistent with a defect in embryonic lymphatic vascular function. 
Besides, another phenotype of E14.5 Adamts3-/- embryos is anemia and fetal liver defect, 
which is phenocopy of Ccbe1-/- embryo (Zou et al., 2013). Investigation of the anemic 
defect, however, is out of scope of this thesis. 
 
 
 
 
 
 
  
Figure 50. Loss of ADAMTS3 results in severe cutaneous edema at E14.5. Arrow indicates 
translucent space between the skin and body indicative of edema.  
 
Histologic examination revealed normal LYVE1+; PROX1+ lymphatic vessel growth in 
the skin and deeper tissues of Adamts3+/- and Adamts3+/+ control littermates, but 
LYVE1+; PROX1+ lymphatic vessels were entirely absent in embryos lacking 
ADAMTS3 (Fig. 51), consistent with a recent report of independently derived Adamts3-/- 
Control Adamts3-/-
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animals (Janssen et al., 2016).  In the skin, macrophages (LYVE1+; PROX1-) fill up the 
space where lymphatic vessels normally locate while the jugular lymph sacs are 
completely missing in Adamts3-deficient embryos.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51. ADAMTS3 is required for lymphatic development in mouse embryos. Loss of ADAMTS3 
results in a complete lack of PROX1+; LYVE1+ lymphatic endothelial cells in the E14.5 embryo. Note 
the presence of smaller lymphatic vessels in the skin (A) and larger lymphatic vessels adjacent to the 
dorsal aorta and cardinal vein (B) in the wild-type littermate control embryo. Scale bars indicate 50 
microns. 
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To assure that ADAMTS3 is lymphatic-specific, we examined the cardiovasculature and 
blood vessel establishments in the E14.5 Adamts3-/- embryos.  PECAM and FLK1 
staining for endothelial cells revealed normal blood vessel patterning and growth in 
Adamts3-/- embryos (Fig. 52), a finding consistent with the observation that Adamts3-/- 
embryos were not growth retarded. These findings closely phenocopy those previously 
reported for both Vegfc-/- (Karkkainen et al., 2014) and Ccbe1-/- (Bos et al., 2011; Zou et 
al., 2013) embryos, and reveal that ADAMTS3 plays an indispensable and non-redundant 
role for lymphatic vascular development in mice. 
 
 
 
 
 
 
 
 
 
 
 
Figure 52. ADAMTS3 is not required for blood vessel development. Blood vessels from an 
ADAMTS3-deficient and control embryo were identified using anti-PECAM and anti-FLK1 
immunostaining. Scale bars indicate 50 microns. 
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5.7 Analysis of the role of VEGFC versus VEGFD in a peritoneal inflammatory 
lymphangiogenesis model 
Since our studies revealed potential distinct mechanisms of regulating lymphangiogenesis 
between VEGFC versus VEGFD, we proposed to test the role of VEGFC vs. VEGFD in 
a peritoneal inflammatory lymphangiogenesis model using adult knockout animals. The 
lipopolysaccharide (LPS)-induced model, previously used by the Koh lab and others to 
measure lymphangiogenic responses in the setting of inflammation (Kim et al., 2009), 
was implemented because lymphatic growth takes place on the peritoneal surface of the 
diaphragm where it can be visualized in its entirety by whole mount staining for 
lymphatic vessels (using anti-LYVE1 antibodies) and quantitated by calculating 
lymphatic vessel area as a % of total area. This investigation was greatly contributed by 
the Alitalo research group (University of Helsinki). The animals used in this assay were 
control animals, adult constitutive Vefgd-deficient animals, and adult animals, in which a 
conditional allele of VEGFC was deleted ubiquitously after tamoxifen administration 
(Vegfcfl/fl; Rosa26-CreERT2).  
Using this peritoneal inflammatory model, we were able to observe a possible trend 
toward reduced inflammatory lymphangiogenesis with loss of VEGFD but not with loss 
of VEGFC (Fig. 53). Unfortunately, the assay demonstrated a high degree of variability 
that ultimately precluded us from drawing any significant conclusions regarding the roles 
of VEGFC and/or VEGFD in inflammatory lymphangiogenesis. In summary, this assay 
did not provide solid evidence to demonstrate the potentially different role of VEGFC vs. 
VEGFD in peritoneal inflammatory lymphangiogenesis.  
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Figure 53. Analysis of VEGFC and VEGFD in an inflammatory lymphangiogenesis model using 
intraperitoneal LPS injection. Diaphragms were fixed in 4% PFA overnight in cold and stained for 
anti-LYVE1 using a standard whole mount protocol. Images were acquired using AzioZoomV16 
microscope equipped with Orca Flash 4 camera and LYVE1 area was quantified using ImageJ. Brush 
painting of the LYVE1 lymphatic vessels was used to improve the contrast and the accuracy of 
quantification. Bars represent the mean ± SEM. Statistical analysis using ordinary one-way ANOVA. 
The assay was done with the help of the Alitalo group. 
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Alitalo lab in Helsinki) and quantitation from fixed diaphragms that were shipped 
to a single site and for blinded staining and lymphatic area calculation by a single 
observer.   
Using this assay we observed a possible trend toward reduced 
inflammatory lymphangiogenesis with loss of VEGFD but not with loss of 
VEGFC, but the assay demonstrated an excessive degree of variability that 
ultimately precluded us from drawing any significant conclusions regarding the 
roles of VEGFC and/or VEGFD in inflammatory lymphangiogenesis (full results 
are shown below in Reviewer Fig. 1).  We do not believe that the failure of these 
studies reflects problems with the animals used because (i) all animals were 2-3 
months in age at the time of use, (ii) all animals were on a pure C57Bl/6 
background, (iii) variability was as high in animals that did not receive tamoxifen 
treatment (e.g. control or VEGFD constitutive KOs) to induce gene deletion as in 
those that did, and (iv) prior studies have demonstrated efficient deletion of 
VEGFC using this approach(2).  Needless to say, these results were quite 
disappointing after many months of careful breeding and experimentation.  The 
main lesson we have drawn from these studies is that, unlike developmental 
studies in which a highly controlled and stereotypic process can be reproducibly 
interrogated, adult inflammatory lymphangiogenic  assays have not yet been 
standardized to the point where these genetic studies are straightforward and 
interpretable.  There are likely many variables that need to be addressed, 
including the type of inflammation (and therefore the type of protease activation), 
the methods available to measure lymphangiogenic growth and lymphatic 
function, and the organ in which the assay is performed.  Thus testing the roles 
of VEGFC and VEGFD in inflammatory lymphangiogenesis will be more 
challenging than we initially thought and will require a separate series of studies 
that employ a number of approaches with quantitative measures of both 
lymphatic vessel growth and function.  We remain committed to doing such 
studies, but it is now clear that they will extend beyond the scope of the present 
manuscript.  We therefore thank Reviewer B for suggesting/encouraging this line 
of investigation, and we hope that future studies will successfully address it. 
 
 
Reviewer Figure 1. Analysis of VEGFC and VEGFD in  inflammatory 
lympha giogenesis model using intraperitoneal LPS.   
C57BL/6J female mice of the indicated genotypes were injected i.p. following a 
previously described protocol with adjustments of the LPS dose and frequency of 
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5.8 Analysis of de novo lymphangiogenesis in a skin wound healing model  
Both VEGFC and VEGFD were reported to enhance lymphatic growth in adult animals 
(Anisimov et al., 2009), however, how these two ligands regulate regeneration of 
lymphatic vessels at injury sites, and what the growth pattern of the these new lymphatics 
is are not yet known. Therefore, an in vivo wound healing model – the full thickness 
excision – was implemented to address this specific question. An injury (1.5cm x 1.5cm) 
was introduced onto dorsal skin of experimental animals (day 0), and the healing process 
is observed within 18 days (Fig. 54). A distinctive feature of the newly healed skin is 
hairless where the new epidermis has closed the wound, however skin morphology has 
not completely restored. This observation was consistent with other previous studies on 
mouse skin wound healing (Shaw and Martin, 2009; Koch et al., 2009).  
 
 
 
 
 
 
Figure 54. Mouse adult dorsal skin was healed within 18 days after full thickness excision. The newly 
healed skin is hairless, which is distinctive to undamaged skin.    
 
 
 
Day 0 Day 18
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The H&E staining provided a brief insight into how the new vasculature growth within 
the wound site (Fig. 55). Undamaged skin has a very thin layer of epidermis while its 
dermis layer expands to most of the skin cross-section. By day 7 after skin excision, the 
inflammatory site was resolved and dried out. No clear sign of the new epidermis layer 
formation before wound contraction around day 10 (data not shown).  The skin was 
healed from day 14 onwards when new epidermis and dermis layers are separated.  
However, the vasculature morphology, especially the new dermis layer was not restored 
to its original condition. The healing process continued to proceed as shown on day 18. 
The new skin on day 18 did not have any hair follicle formation, which explained why it 
was hairless. This observation suggested the mouse skin healing could be achieved in the 
first two weeks, then followed up by structural remodeling until the resolution phase is 
complete.  
 
Figure 55. Mouse skin wound healing process by H&E staining. On day 0, undamaged skin of adult 
animals was used as control for healing end-point, which had not been achieved by day 18. The new 
epidermis and dermis layers were separated between day 7 and day 14. The new skin has no hair 
follicle formation.       
Day 0 Day 7
Day 14 Day 18
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Mouse skins were harvested at different time points and cross-sections were examined by 
histology staining with LYVE1+ and PROX1+ antibodies for lymphatic distribution in the 
skin. In undamaged skin, LYVE1+; PROX1+ lymphatic vessels mostly localize in the 
dermis and subcutaneous layers (Fig. 56). The epidermis-specific staining of K14 
revealed that lymphatics are exclusive from the epidermis layer.  
 
 
 
 
 
 
 
 
  
 
 
 
Figure 56.  Lymphatic distribution in the adult mouse skin. (A) Lymphatic vessels were detected 
using LYVE1 and PROX1 immunostaining at 10x magnification. (B) Detection of the epidermis layer 
(K14+) in undamaged skin. (C, D) Analysis of lymphatic vessels (LYVE1+; PROX1+) at higher 
magnification (40x). Arrows indicate lymphatic vessels. 
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No lymphatic vessel was detected in the injury sites on day 4 after the surgery was 
performed (Fig. 57). This observation confirmed that the skin healing is a de novo 
lymphatic regeneration process from complete absence of lymphatic vessels in this 
model. In addition, no detection of a new epidermis layer (K14+) was detected at this 
time point. 
 
 
 
 
 
 
 
Figure 57.  No lymphatic vessel (LYVE1+; PROX1+) was detected on day 4 after surgery; at (A) 10x 
magnification, and (B) 40x magnification.  
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Lymphatic (LYVE1+; PROX1+) vessels started to show up on day 7, mostly in the 
subcutaneous area where new skin attached to the dorsal spinal muscles. These 
lymphatics were large vessels with high number of PROX1+ nuclei (Fig. 58).  In contrast, 
no LYVE1+; PROX1+ vessels was detected in the new dermis layer at this point.  This 
observation suggested that new lymphatics potentially grow upwards from subcutaneous 
tissues, rather than by reconnecting existing lymphatic vasculature around injury site. 
Besides, no K14+ staining was detected, implying an incomplete formation of a new 
epidermis layer.  
 
 
 
 
 
 
 
 
 
 
Figure 58.  New lymphatic regeneration on day 7 after the full thickness excision. (A) Lymphatic 
(LYVE1+; PROX1+) vessels were mostly detected in the subcutaneous areas (4x magnification). (B) 
No detection of the new epidermis layer (K14+) in day 7 skin. (C) No lymphatic vessel was detected in 
the new dermis layer; (D) Robust growth of subcutaneous LYVE1+; PROX1+ vessels (40x 
magnification). Arrows indicate lymphatic vessels. 
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By day 14, new lymphatics (LYVE1+; PROX1+) were detected in both new dermis and 
subcutaneous layers (Fig. 59). The lymphatic vessels on day 14 were relatively smaller in 
size compared to those detected on day 7.  In combination with what was observed on 
day 7, in vivo observations suggested that lymphatic vessels could migrate from the 
subcutaneous area into the new dermis layer from day 7 to day 14 after the surgery. 
Moreover, the new epidermis layer (K14+) was completely formed at this time point.   
 
 
 
 
 
 
 
 
 
 
Figure 59.  New lymphatic regeneration on day 14 after the full thickness excision. (A) Lymphatic 
(LYVE1+; PROX1+) vessels were detected in the dermis and subcutaneous areas (4x magnification). 
(B) The complete epidermis layer (K14+) was formed by day 14 after the surgery. (C, D) New 
lymphatic vessels were in the dermis and subcutaneous at 40x magnification, respectively. Arrows 
indicate lymphatic vessels. 
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On day 18, the overall structure of the newly healed skin was similar to that was observed 
on day 14 (Fig. 60). Although dermis lymphatics started to separate themselves towards 
upper areas of the dermis layer, morphology of the new skin was still significantly 
different to undamaged skin. This suggested further remodeling must be required to 
achieve complete restoration. However, lymphatic regeneration looked complete at this 
time point. In order to confirm this observation, the number of new lymphatic vessels 
were quantified and compared between different time points.  
 
 
 
 
 
 
 
 
   
 
Figure 60.  Further lymphatic regeneration on day 18 after the full thickness excision. (A) Lymphatic 
(LYVE1+; PROX1+) vessels were detected in the dermis and subcutaneous areas (10x magnification). 
(B) The complete epidermis layer (K14+) of the new skin. (C, D) New lymphatic vessels were in the 
dermis and subcutaneous at 40x magnification. Arrows indicate lymphatic vessels. 
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To illustrate the process of lymphatic growth during wound healing, the number of 
lymphatic (LYVE1+; PROX1+) vessels were counted in 40 different high power fields 
(40X Objective and 10X Ocular ~ 2.37mm2) for each experimental animal at different 
time points, i.e. day 4, day 7, day 14, and day 18. The quantitative result was consistent 
with our visual observations, and confirmed near completion of lymphatic regeneration 
by day 18 after the surgery (Fig. 61). Thus, this model of de novo lymphatic generation 
has been validated by both qualitative and quantitative approaches for future study of 
lymphangiogenesis during wound healing.   
 
 
 
 
 
 
 
 
 
 
 
Figure 61. Quantification analysis of lymphatic regeneration in dorsal skin wound healing. Skins were 
fixed, sectioned, and stained for LYVE1 PROX1 antibodies.  The number of LYVE1+; PROX1+ 
vessels per high power field were manually counted with a Nikon Eclipse 80i microscope. Bars 
represent the mean ± SEM. Statistical analysis using ordinary one-way ANOVA. The number N for 
each group provided underneath. *** indicates P<0.001. 
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5.9 Chapter discussion 
CCBE1 has clearly demonstrated, according to our in vitro experiments, as a required 
cofactor to facilitate VEGFC processing complex assembly. Here, our in vivo conditional 
Ccbe1-deficient mouse model provided a unique opportunity to study the role of CCBE1 
during adulthood, when the lymphatic vasculature has completely established. The 
tamoxifen inducible system was extremely helpful for inducing CCBE1 deletion at timely 
manner. To our surprise, CCBE1 is required for new lymphatic growth after birth, but not 
for the maintenance of mature lymphatic vasculature. In addition, the in vivo observation 
that loss of VEGFC responsiveness in Ccbe1-deficient animals can be rescued by the 
fully processed active ligand VEGFCΔNΔC supports our in vitro findings and a mechanism 
in which CCBE1 participated in VEGFC proteolysis in vivo. The lymphatic structures 
generated in response to VEGFCΔNΔC expression in the muscle of mature mice appeared 
highly abnormal as they tightly encircled the muscle fibers that expressed VEGFCΔNΔC 
and did not form typical branching structures. In contrast, full length VEGFC stimulated 
the growth of branched lymphatic structures, presumably due to the influence of 
endogenous regulators such as CCBE1 and ADAMTS3. Thus, this implies the regulation 
of VEGFC proteolysis in vivo can be highly temporal and spatial, which may be 
disrupted by simple over-expression of either CCBE1 or ADAMTS3 in vitro. 
Why has CCBE1 evolved to play such an important role in the growth of lymphatic but 
not blood vessels? During development, once the programmed vasculogenesis is 
completed, blood vessels expand organically with growing organs in order to feed the 
rising cell population (Potente et al., 2011). On the other hand, lymphatic vessels grow 
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rapidly after organs have already formed and achieved a large enough size to require 
lymphatic drainage. It is likely that CCBE1 and ADAMTS3 provide a spatial intersection 
pattern with VEGFC to create a trail of active ligands to promote LECs migration. In 
other words, the primary role of ADAMTS3-CCBE1 is to lay down a roadmap for LECs 
to follow and rapidly create the primary lymphatic network (Fig. 62). Such a precise 
spatiotemporal blueprint may be required for the lymphatic vasculature to expand as 
rapidly as it does in mid-gestation, e.g. from a limited number of progenitor cells to a 
functional network in only a few days in the mouse embryos.    
 
 
 
 
 
 
 
 
Figure 62. Proposed lymphangiogenic roles VEGFC in vivo. VEGFC activation by ADAMTS3 and 
CCBE1 provide a mechanism for spatial patterning of the developing lymphatic vasculature. The mid-
gestation cardinal vein with newly specified LECs that are in the process of sprouting to form the 
lymphatic network is shown. The area encircled by the dotted line represents a zone of active VEGFC. 
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It is surprising that, despite its redundant function with ADAMTS2 for procollagen 
processing (Colige et al., 2005) and close homology to ADAMTS14 (Bolz et al., 2001), 
ADAMTS3 plays a non-redundant role in lymphatic development in mice. Adamts3-/- 
animals phenocopy the phenotypes of Vegfc-/- and Ccbe1-/- mice that provided solid 
evidence for existence of VEGFC processing complex in vivo, as previously 
demonstrated in our biochemical assays. The strong physical association observed 
between ADAMTS3 and CCBE1 in our studies suggests that the functions of these two 
proteins are tightly linked. Mutations in CCBE1 account for only 25% of Hennekam 
syndrome cases (Alders et al., 2009; Alders et al., 2013). The highly specific disruption 
of lymphatic development with loss of ADAMTS3 in developing mice suggests that loss 
of function mutations in ADAMTS3 may also contribute to Hennekam syndrome.  Future 
studies addressing the biochemical and genetic relationships between of these proteins 
will better define how this complex regulates lymphangiogenesis in vivo as well as its 
contribution to human lymphatic diseases. 
The peritoneal lymphangiogenesis model was used to examine the requirement of 
VEGFC and VEGFD in inflammatory lymphangiogenesis in adult animals that were 
engineered to genetically lack VEGFC, VEGFD, and both VEGFC and VEGFD. 
Although an excessive degree of variability was observed in our results, we do not 
believe that the failure of these studies reflects problems with the animals used. Firstly, 
all animals were 2-3 months in age at the time of use and were on a pure C57Bl/6 
background. Second, variability was as high in animals that did not receive tamoxifen 
treatment (e.g. control or VEGFD constitutive KOs) to induce gene deletion as in those 
that did (e.g. VEGFC conditional KO). Third, the assay was performed independently 
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from two different laboratories. It is possible that, unlike developmental studies in which 
a highly controlled and stereotypic process can be reproducibly interrogated, adult 
inflammatory lymphangiogenic assay has not yet been standardized to the point where 
these genetic studies are straightforward and interpretable. There are likely many 
variables that need to be addressed, including the type of inflammation (and therefore the 
type of protease activation), the methods available to measure lymphangiogenic growth 
and lymphatic function, and the organ in which the assay is performed. Thus testing the 
roles of VEGFC and VEGFD in inflammatory lymphangiogenesis is challenging and 
requires an established model with quantitative measures of both lymphatic vessel growth 
and function.  
In search for a quantitative approach to examine the roles of VEGFC and VEGFD in 
adult lymphangiogenesis, we pursued a model in which lymphatic growth is a local 
process that is served by serine proteases like plasmin, which activates VEGFD by 
cleavage at a distinct N terminal sequence. The full thickness excision, which completely 
removed an area of dorsal skin at the site of injury, is a potential candidate model as the 
wound healing process provides high abundance of plasmin and other serine proteases. In 
the same context, our adeno-virus injection assays showed that CCBE1/ADAMTS3 are 
active to process VEGFC and VEGFC can promote lymphangiogenesis in the skin. The 
dorsal skin wound healing, where both VEGFC and VEGFD are active, is the model to 
study roles of these lymphangiogenic ligands during adulthood. To our interest, new 
lymphatics did not reconnect from the existing lymphatic vasculature surrounding the 
injury site. Instead, new lymphatic vessels budded out from subcutaneous tissues, and 
then migrated upwards to the new dermis layer (Fig. 63). Importantly, we were able to 
106 
quantify the number of new lymphatic (LYVE1+; PROX1+) vessels at specific time 
points during wound healing process. Thus, this assay provided a novel tool to study de 
novo lymphangiogenesis in adult animals, rather than a conventional lymphatic 
regeneration model. We believe the full thickness excision assay could answer the 
question whether or not the roles of VEGFC and VEGFD are distinct in adult 
lymphangiogenesis. Indeed, our next step would be to apply this procedure to VEGFC 
conditional KO, VEGFD KO, and VEGFC/VEGFD double KO animals to identify the 
roles of each lymphangiogenic factor in new lymphatic development in adulthood. If 
VEGFD, but not VEGFC, is responsible for adult de novo lymphangiogenesis, the wound 
healing process in VEGFD KO and VEGFC/ VEGFD double KO animals are expected to 
be similar, whereas VEGFC condition KO animal should not display any abnormalities 
compared to control animals. A similar rationale could be applied if VEGFC, but not 
VEGFD, drives lymphangiogenesis in adult skin healing. However, if VEGFC and 
VEGFD work redundantly in adulthood, the double KO animals are expected to show 
complete loss of lymphatic growth, whereas VEGFC conditional KO or VEGFD KO 
only display partial loss of lymphangiogenesis compared to control animals. The 
conclusion drawn from this study might provide a novel insight into the functions of 
VEGFD, which has not yet been fully understood, and the relationship between the two 
lymphangiogenic factors.  
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Figure 63. Model of de novo lymphangiogenesis in adult mouse skin. The full thickness excision 
procedure removed epidermis and dermis layers from skin on day 0. A fibrin mess (including fibrins 
and other ECM proteins) was formed to fill up the injury site. On day 7, new lymphatic vessels were 
detected in the subcutaneous region and migrated upwards to the new dermis layer until day 14, when 
the new epidermis layer was completely formed.    
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CHAPTER SIX 
Discussion and Conclusion 
During embryonic development, lymphatic vessels arise after organs have formed and 
rapidly create a vascular network through a highly stereotyped, spatially controlled 
angiogenic program (Yang and Oliver, 2014). VEGFC is a critical regulator of this 
process (Karkkainen et al., 2004; Ober et al., 2004), but the VEGFC homologue VEGFD 
appears to play no required role in lymphatic development (Koch et al., 2009). VEGFC 
and VEGFD contain N and C terminal extensions that are not found in VEGFA. Cell 
culture studies performed almost 20 years ago first revealed that these extensions are 
proteolytically removed (Joukov et al., 1997; Stacker et al., 1999), but the biological 
significance of these observations has only recently begun to emerge from studies 
connecting defects in lymphatic development associated with loss of the secreted protein 
CCBE1 and a role for CCBE1 in VEGFC proteolysis (Jeltsch et al., 2014; Le Guen et al., 
2014; Roukens et al., 2015). However, a clear molecular understanding of these events 
has not yet emerged due to difficulties in following VEGFC proteolysis, assessing its role 
in lymphatic endothelial cell responses ex vivo and in vivo, and a lack of evidence 
supporting a role for ADAMTS3 in lymphatic development. Our studies have addressed 
these issues using molecular tags to follow VEGFC and VEGFD processing without 
disturbing their molecular activity, genome editing to test the role of ADAMTS3 ex vivo, 
and mouse genetic studies to test the roles of ADAMTS3 and CCBE1 in vivo. We find 
that assembly of a VEGFC-ADAMTS3-CCBE1 complex regulates VEGFC activity, and 
that loss of ADAMTS3 blocks lymphatic development in mice in a manner identical to 
loss of CCBE1 or VEGFC. In contrast, proteolysis of the closely related VEGFD, a 
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growth factor that is dispensable during lymphatic development, is independent of 
ADAMTS3 and CCBE1 ex vivo and its lymphangiogenic activity independent of CCBE1 
in vivo. These findings suggest that regulation of VEGFC activity by ADAMTS3 and 
CCBE1 is a molecular mechanism for programmed lymphatic growth during 
development, while the role of VEGFD may be connected to lymphangiogenesis that 
takes place after lymphatic development is complete and regulated by a distinct 
proteolytic activation mechanism.  
One of our challenges in pursuing this study further is to understand how the spatial 
relationship of VEGFC, ADAMTS3 and CCBE1 is important for productive 
lymphangiogenesis. This question is raised after the fact that VEGFC ligands under in 
vitro condition takes 18 hours to complete its NT cleavage, which is significantly longer 
than rapid LEC sprouting that has been observed in vivo. The rationale to explain this 
long incubation time is due to the HEK293T conditioned media environment where 
secreted proteins are free to move and interact by chance. As freely as they move, it 
might take longer time for all components of the VEGFC-ADAMTS3-CCBE1 complex 
to assemble to perform proteolysis. In contrast, tight regulation of in vivo VEGFC 
processing by	  spatial intersection of ADAMTS3 and CCBE1 proteins in the extracellular 
environment provides a previse roadmap for rapid ligand activation, which leads to LEC 
sprouting and lymphatic growth. This notion is supported by our in vivo data showing 
that full length VEGFC expression promotes normal growth of lymphatic structures in 
the muscle of mature mice, presumably due to regulation of endogenous CCBE1 and 
ADAMTS3. However, the processed ligand VEGFCΔNΔC that bypasses the regulation of 
CCBE1/ ADAMTS3 generates highly abnormal lymphatic structures and impairs the 
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typical lymphatic branches. To understand the spatial relationship between these secreted 
proteins, it is necessary to use mouse genetics with organ-specific Cre recombinases to 
knockout each protein in potential organs and areas of interest. Observation of lethality or 
significant phenotypes should indicate whether VEGFC or ADAMTS3 or CCBE1 is 
expressed in a specific organ/ tissue, illustrating its source of expression. The selection 
criteria of Cre recombinases is to target organs/ tissues, which surround areas of the 
cardinal vein – the origin of LEC progenitors, and of the lymph sacs - the first lymphatic 
vessels. Examples of potential Cre recombinases used in this study are Wt1-Cre 
(mesothelium), SM22a-Cre (smooth muscle cells), Fsp1-Cre (fibroblasts), and Vav-Cre 
(hematopoietic and endothelial cells). The location where each of these proteins is 
expressed could provide an idea of how they spatially come to contact with one another. 
A further step in studying the VEGFC-ADAMTS3-CCBE1 complex in vivo is to 
engineer mouse genome with fluorophore-tag like mCherry or GFP or Cyan Fluorescent 
Protein (CFP) to each component of the VEGFC processing complex. In the past, 
transgenic VEGFA-GFP mouse was generated by Kishimoto et al., which suggested the 
possibility of following VEGFC in vivo (Kishimoto et al., 2000). The gene editing 
technology of CRISPR/ Cas9 in mice potentially allows transformation of in vitro genetic 
modifications into transgenic mice in a more robust and convenient way than the 
conventional method (Oji et al., 2016). Mice carrying fluorophore-tagged of VEGFC, 
CCBE1, and ADAMTS3 could be analyzed by frozen section IHC to provide insight into 
the complex assembly and spatial relationship between these secreted lymphangiogenic 
factors in vivo. Our new understanding of VEGFC proteolysis mechanism and available 
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technologies for transgenic mice generation could make it feasible to observe and analyze 
the VEGFC processing complex in vivo in the near future.    
There remains a molecular question of precisely how proteolysis activates the VEGFC 
ligand to drive lymphatic development and growth. Our findings and previous studies 
clearly demonstrate a requirement for proteolytic removal of N and C termini that are 
covalently linked to each other for VEGFC to activate the VEGFR3 receptor. Several 
molecular mechanisms may explain this requirement. The most straightforward 
mechanism is that the presence of the N and C termini sterically prevents the VEGFC 
core ligand (i.e. the VHD) from engaging the VEGFR3 receptor to induce receptor 
signaling. Alternatively, the N or C terminus may actively oppose VEGFC activity, e.g. 
by binding a distinct site in VEGFR3 or VEGFC itself. In the course of our studies, we 
generated a VEGFC ligand that had an uncleavable 192 amino acid C terminus, one in 
which the C-terminus was replaced with a 22 amino acid FLAG-V5 tag, and one in which 
there was no C terminus following the VHD. All of these ligands were efficiently cleaved 
at the N terminus, but we observed a progressive loss of VEGFR3 activation as the C 
terminal extension grew in length from 0 to 22 to 192 amino acids. The progressive loss 
of function conferred by longer C terminal tags supports the more straightforward model 
of steric hindrance during VEGFC docking to VEGFR3 (Leppanen et al., 2013). This 
also explains if N terminus is not completely removed from VHD, C terminus linked to N 
terminus by a disulfide bond could block receptor binding of VHD.  Thus, the importance 
of proteolytic processing for VEGFC is that the ligand cannot activate VEGFR3 until it is 
fully activated at a precise location of available CCBE1 and ADAMTS3. This tight 
regulation of VEGFC activation is beneficial for lymphangiogenesis in vivo to prevent 
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non-specific lymphatic sprouting and to preserve the role of VEGFC to be lymphatic-
specific. Mutagenesis of cysteine residues, which form disulfide bonds, is a potential 
direction to further understand how C terminus prevents VEGFC binding to VEGFR3. 
Since N and C termini are linked to each other by a disulfide bond, mutation of cysteine 
amino acids could disrupt this connection, which separates these fragments during the 
formation of prepro-VEGFC and completely remove C termini from pro-VEGFC. 
Although there are 8 cysteine residues available on the C terminus, the N terminus of 
VEGFC contains only one cysteine residue, i.e. C83. Conversions of C83 (a polar residue) 
into alanine (A) or phenylalanine (F) (non-polar residues), or into lysine (K) or glutamic 
acid (E) (charged residues) are potential options for mutagenesis. Analysis of C83 mutants 
by VEGFC cleavage assay and phosphor-VEGFR3 ELISA assay could indicate how 
deletion of the disulfide bond contribute to activation of VEGFC, thus suggests the 
importance of C terminus in regulation of VEGFC activity.  
We propose a biological model in which VEGFC signaling is controlled by ADAMTS3 
while VEGFD signaling is controlled by serine proteases, corresponding to roles in 
developmental and inflammatory/ wound lymphangiogenesis, respectively. Although we 
have gained a novel understanding of VEGFC processing, not much has been known 
about regulation of VEGFD proteolysis. That serine proteases like plasmin and thrombin 
have been shown to enhance VEGFD proteolysis suggests a question whether VEGFD 
activation is strictly regulated or VEGFD is a common substrate of several serine 
proteases. To have a better understanding to this question, VEGFD-V5 construct can be 
generated, expressed in HEK293T, and used for co-immunoprecipitation with any 
proteins bind to VEGFD at 4oC and/ or in addition of serine protease inhibitors. The 
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presence of inhibitors and low temperature would inhibit any enzymatic activity and 
maintain the complex of VEGFD and its binding proteins. The VEGFD-binding proteins 
are then isolated and analyzed by mass spectrometry to identify all potential serine 
proteases that bind and cleave VEGFD N terminus.  The results would reveal how tightly 
VEGFD proteolysis is regulated and lead to a better knowledge of why evolution brings 
forth VEGFD, which undergoes similar proteolytic activation like VEGFC but does not 
play a significant role in lymphangiogenesis.   
Lymphedema is a common clinical condition in our society, there are approximately 10 
million people suffering from lymphedema (mostly secondary lymphedema) in the 
United States. The most common cause of secondary lymphedema is due to damage to 
lymph nodes in surgeries and cancer treatment. Such damage interrupts the flow of lymph 
on its way back to the circulation through the subclavian vein that results in tissue 
swelling. Currently, there is no cure for this condition and no mouse model for secondary 
lymphedema. To search for a potential therapeutic approach to mitigate this clinical 
condition, a reliable mouse model for secondary lymphedema is required. The axillary 
lymph node dissection (ALND) procedure should be tested on adult VEGFC or CCBE1 
conditional KO mice to generate a mouse model for secondary lymphedema. Mendez et 
al. applied the ALND model on wild-type mice and reported that the endogenous 
regrowth of collateral lymphatic channels restores	  interstitial fluid drainage, which results 
in an ineffective lymphedema model (Mendez et al., 2012). However, all lymphatic 
factors are active in wild-type mouse, it is expected that endogenous lymphatic 
regeneration could remedy impaired lymph flow caused by removal of axillary lymph 
nodes. In CCBE1 and VEGFC conditional KO adult animals under ALND treatment, the 
114 
lack of endogenous lymphatic growth factor would significantly reduce or even inhibit 
new lymphatic growth that maintain blockages to lymph flow, lead to tissue swelling and 
lymphedema. This investigation could confirm the role of VEGFC in new lymphatic 
growth in adult animals in addition to the study of wound healing. The lymphedema 
mouse model might become a novel tool used to identify potential treatment for 
lymphedema. A previous study reported that administration of adenovirally delivered 
VEGFC enhanced growth of lymphatic capillaries and formation of collecting lymphatic 
vessels in mice after lymph node removal (Tammela et al., 2007). According to Tammela 
et al., newly generated lymphatic vessels can mature and become functional even without 
the presence of lymph nodes. However, it has not been known if VEGFC can restore 
lymph flow in mice with lymphedema due to the lack of a reliable animal model. The 
outcome of this study promises a novel insight into clinical treatment for lymphedema. 
Moreover, our understanding of VEGFC activity regulation demonstrates that CCBE1 
and ADAMTS3 are as important lymphatic factors as VEGFC. This notion broadens 
potential therapeutic options for lymphedema treatment. The use of CCBE1 and 
ADAMTS3, which are regulatory proteins, could help avoid non-specific lymphatic 
growth that might be caused by direct administration of VEGFC. Also, patients with 
deficiency in CCBE1 or ADAMTS3 due to genetic mutations display similar symptoms 
as those who have VEGFC mutations, but are not helped by VEGFC treatment. The roles 
of CCBE1 and ADAMTS3 in lymphatic regeneration have not yet been fully 
characterized and understood, therefore, it is reasonable to examine effects of CCBE1 
and ADAMTS3 in adult lymphangiogenesis. Further investigations on the VEGFC-
ADAMTS3-CCBE1 complex are required to gain deeper knowledge and practical 
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understanding to identify a potential cure for impaired lymphatic vasculature; it is a 
glimpse of hope for patients with lymphedema. 
In conclusion, our research has contributed to the discovery of such diverse and complex 
regulatory mechanisms in which VEGFC activation reveals an unexpected complexity in 
the control of lymphatic vascular growth. While further studies are necessary to translate 
our findings into therapeutic applications for lymphatic defects in human, understanding 
of VEGFC/ CCBE1/ ADAMTS3 pathway should encourage use of these growth factors 
in therapy for lymphatic diseases including lymphedema.  
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